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Abstract	  
	  
Sepsis	  is	  an	  old	  and	  lethal	  disease	  caused	  by	  immune	  dysfunction	  in	  response	  to	  
infection.	  The	  innate	  immune	  system	  is	  the	  first	  responder	  to	  infection	  and	  the	  first	  to	  
dysfunction.	  It	  comprises	  both	  humoral	  and	  cellular	  components	  such	  as	  the	  
complement,	  coagulation	  and	  fibrinolytic	  cascade	  systems	  as	  well	  as	  the	  
polymorphonuclear	  neutrophils	  and	  monocytes.	  These	  usually	  recognize	  and	  respond	  to	  
pathogens	  in	  an	  orderly	  fashion,	  leading	  to	  resolution	  of	  infection	  and	  restored	  
homeostasis.	  However,	  in	  sepsis	  the	  response	  is	  first	  exaggerated	  and	  later	  reduced	  or	  
even	  non-­‐existent.	  As	  of	  today,	  patients	  suffering	  from	  sepsis	  only	  receive	  antibiotic	  and	  
supportive	  treatment.	  
The	  Gram-­‐positive	  bacterium	  Staphylococcus	  aureus	  is	  a	  frequent	  cause	  of	  infection	  and	  
sepsis.	  It	  is	  well	  known	  for	  its	  wide	  antibiotic	  resistance	  and	  ability	  to	  survive	  within	  
humans.	  Several	  membrane-­‐bound	  and	  secreted	  proteins	  promote	  staphylococcal	  
infection	  by	  inactivating	  complement,	  surviving	  within	  phagocytes	  and	  exploiting	  
coagulation	  to	  disseminate	  with	  the	  host.	  However,	  an	  overview	  of	  the	  mechanisms	  and	  
virulence	  factors	  involved	  is	  currently	  not	  found.	  
This	  review	  therefore	  covers	  documented	  interactions	  between	  S.	  aureus	  and	  the	  
complement	  system,	  the	  coagulation	  and	  fibrinolytic	  systems	  as	  well	  as	  neutrophils	  and	  
monocytes	  in	  infection	  and	  sepsis	  following	  a	  brief	  introduction	  to	  each	  topic.	  The	  aim	  is	  
to	  give	  both	  the	  reader	  and	  the	  writer	  an	  overview	  of	  the	  current	  knowledge	  and	  
ongoing	  research.	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Sepsis	  -­‐	  an	  introduction	  
Sepsis	  is	  as	  fascinating	  as	  it	  is	  old.	  Its	  Greek	  translation	  reads	  the	  "decomposition	  of	  
animal,	  or	  vegetable	  or	  organic	  matter	  in	  the	  presence	  of	  bacteria",	  described	  by	  Homer	  
over	  2700	  years	  ago	  as	  a	  derivative	  of	  "I	  rot"	  (1).	  Today,	  by	  definition,	  sepsis	  designates	  
a	  collection	  of	  clinical	  findings	  on	  the	  basis	  of	  confirmed	  infectious	  origin;	  a	  temperature	  
above	  38	  or	  below	  36	  degrees	  Celsius,	  a	  heart	  rate	  greater	  than	  90	  beats	  per	  minute,	  a	  
respiratory	  rate	  greater	  than	  20	  breaths	  per	  minute	  (or	  an	  arterial	  carbon	  dioxide	  
concentration,	  PaCO2,	  less	  than	  4.3	  kPa),	  and	  a	  white	  blood	  cell	  count	  either	  greater	  than	  
12	  x	  109	  or	  less	  than	  4	  x	  109	  cells	  per	  mL	  (2).	  These	  are	  the	  criteria	  of	  the	  systemic	  
inflammatory	  response	  syndrome	  (SIRS),	  arising	  in	  both	  sterile	  and	  infectious	  
inflammation,	  but	  sepsis	  is	  only	  true	  for	  the	  latter,	  when	  two	  or	  more	  of	  the	  SIRS	  criteria	  
are	  met	  as	  well.	  	  
Importantly,	  the	  consensus	  conference	  where	  these	  criteria	  were	  defined	  marked	  a	  
turning	  point	  in	  our	  understanding	  of	  sepsis	  -­‐	  it	  is	  no	  longer	  caused	  by	  the	  infectious	  
agent,	  but	  rather	  by	  the	  immune	  system's	  exaggerated	  response	  to	  it.	  Since	  then,	  this	  
response	  has	  been	  studied	  thoroughly	  but	  is	  still	  difficult	  to	  fully	  comprehend.	  The	  late	  
Roger	  C.	  Bone	  summarized	  the	  septic	  pathogenesis	  as	  "a	  cascade	  that	  is	  initiated	  by	  a	  
focus	  of	  infection	  or	  injury	  and	  ends	  with	  severe	  endothelial	  damage,	  profound	  
hemodynamic	  derangements	  and,	  often,	  death"	  (3).	  Indeed,	  if	  left	  unchallenged,	  sepsis	  
progresses	  to	  severe	  sepsis	  with	  organ	  dysfunction,	  hypoperfusion	  and/or	  hypotension,	  
and	  ultimately,	  it	  progresses	  to	  septic	  shock	  -­‐	  a	  state	  of	  refractory	  hypotension	  
demanding	  aggressive	  supportive	  therapy	  -­‐	  multiple	  organ	  failure	  and	  death	  (2).	  Over	  
the	  last	  years	  however,	  the	  idea	  of	  a	  singularly	  exaggerated	  immune	  response	  has	  been	  
questioned.	  Partly,	  because	  the	  promising	  results	  of	  immunomodulatory	  therapy	  in	  
allegedly	  flawed	  animal	  models	  failed	  to	  apply	  in	  the	  human	  setting	  (4,	  5),	  and	  partly	  
because	  the	  pathogenesis	  of	  sepsis	  and	  septic	  shock	  turned	  out	  to	  be	  both	  pro-­‐	  and	  anti-­‐
inflammatory	  (6).	  Nonetheless,	  the	  hypothesis	  remains.	  The	  infective	  agent	  merely	  
topples	  the	  first	  domino.	  This	  process	  is	  also	  extensively	  reviewed	  elsewhere	  (7,	  8)	  
The	  regulated	  inflammation	  of	  infection	  is	  primarily	  a	  physiological	  and	  protective	  
process	  meant	  to	  restore	  homeostasis	  (9).	  It	  basically	  revolves	  around	  the	  three	  R's	  -­‐	  
recognition,	  response	  and	  resolution:	  The	  immune	  system,	  recognizes	  the	  infective	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agent.	  It	  then	  initiates	  a	  proportional,	  well-­‐orchestrated	  response	  aimed	  at	  destroying	  
the	  agent	  with	  minimal	  collateral	  tissue	  damage.	  Upon	  clearance	  of	  both	  the	  infective	  
agent	  and	  the	  activated	  immune	  components	  homeostasis	  is	  restored.	  In	  sepsis,	  
however,	  the	  response	  is	  disproportional.	  
At	  first,	  bacterial	  endotoxin	  or	  lipopolysaccharide	  (LPS)	  of	  the	  Gram-­‐negative	  cell	  wall	  
was	  the	  main	  suspect.	  LPS	  was	  therefore	  used	  in	  several	  animal	  models.	  Circulating	  and	  
membrane-­‐bound	  receptors	  on	  the	  cells	  of	  the	  immune	  system,	  notably	  
polymorphonuclear	  neutrophils	  (PMNs),	  recognize	  LPS	  and	  transcript	  and	  release	  
cytokines,	  the	  "hormones"	  of	  inflammation	  (7,	  10).	  The	  use	  of	  LPS	  alone,	  however,	  
proved	  too	  simplistic.	  First	  	  because	  bacteria	  stripped	  of	  LPS	  could	  initiate	  similar	  
effects,	  albeit	  at	  higher	  concentrations	  (11).	  Second	  and	  more	  important,	  because	  at	  
least	  half	  of	  all	  cases	  of	  sepsis	  are	  caused	  by	  Gram-­‐positive	  bacteria	  (12)	  lacking	  LPS	  
altogether.	  Even	  so,	  the	  immune	  system	  does	  initiate	  a	  harmful	  response	  to	  infection	  in	  
sepsis.	  It	  starts	  with	  innate	  immune	  recognition	  of	  the	  infective	  agent's	  pathogen	  
associated	  molecular	  patterns	  (PAMPs).	  Also	  the	  damage	  associated	  molecular	  patterns	  
(DAMPs)	  exposed	  by	  the	  infective	  agent's	  virulence	  factors.	  e.g.	  exposed	  intracellular	  
proteins	  in	  response	  to	  pore-­‐forming	  toxins	  –	  could	  be	  recognized.	  Most	  commonly,	  the	  
infection	  originates	  from	  either	  pneumonia	  or	  an	  intra-­‐abdominal	  or	  urinary	  tract	  
infection	  (13).	  Together	  with	  leukocyte	  activation,	  the	  activation	  of	  the	  innate	  immune	  
system	  includes	  activation	  of	  the	  plasma	  proteolytic	  cascade	  systems:	  The	  complement	  
system,	  the	  coagulation	  system,	  the	  fibrinolytic	  system	  and	  the	  kallikrein-­‐kinin	  or	  
contact	  system	  (14-­‐18).	  	  	  
The	  innate	  immune	  system	  -­‐	  as	  any	  biological	  system	  maintaining	  homeostasis	  -­‐	  consists	  
of	  afferent	  or	  sensing	  components	  that	  register	  disturbances	  (here	  pathogens).	  The	  
effectors	  or	  efferent	  components	  mount	  a	  response	  aimed	  at	  resolving	  these	  
disturbances	  (19).	  The	  afferent	  and	  efferent	  components	  consist	  of	  both	  soluble	  and	  
cellular	  components.	  This	  division	  is	  a	  more	  common	  albeit	  simplified	  way	  of	  portraying	  
the	  immune	  system	  (20).	  The	  soluble	  components	  include	  the	  plasma	  cascade	  systems	  
as	  well	  as	  the	  naturally	  occurring	  antibodies	  and	  the	  pentraxins.	  The	  cellular	  
components	  are	  activated	  through	  their	  pattern	  recognition	  receptors	  (PRRs)	  in	  contact	  
with	  conserved	  structures	  of	  pathogen	  or	  damaged	  self	  (Fig.	  1)	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Figure	  1:	  Overview	  of	  innate	  immune	  components	  involved	  in	  S.	  aureus	  infection.	  Topics	  covered	  in	  this	  
review	  are	  circled	  in	  red.	  
The	  aim	  of	  this	  review	  is	  therefore	  to	  explore	  the	  current	  literature	  on	  how	  some	  of	  
these	  key	  components	  function	  and	  dysfunction	  in	  response	  to	  the	  prime	  Gram-­‐positive	  
pathogen,	  Staphylococcus	  aureus	  -­‐	  the	  most	  frequently	  isolated	  Gram-­‐positive	  bacterium	  
in	  human	  sepsis	  and	  an	  expert	  in	  immune	  evasion	  and	  exploitation.	  Whereas	  the	  
introductory	  paragraphs	  cites	  existing	  solid	  reviews,	  the	  passages	  concerning	  
staphylococcal	  interaction	  with	  the	  innate	  immune	  system	  comprises	  all	  relevant	  papers	  
found	  using	  the	  medical	  subject	  headings	  (MeSH).	  In	  brief,	  "Staphylococcus	  aureus"	  was	  
combined	  with	  the	  different	  subjects	  shown	  in	  figure	  1.	  The	  results	  were	  then	  sorted	  
into	  different	  categories	  that	  later	  made	  up	  the	  subheadings	  to	  the	  chapters	  of	  this	  
Review.	  The	  articles	  were	  collected	  from	  August	  2013	  through	  March	  2014,	  the	  first	  
draft	  was	  written	  in	  April	  2014	  and	  final	  revisions	  were	  made	  in	  May	  2014.	  In	  addition	  
to	  professor	  and	  supervisor	  Tom	  Eirik	  Mollnes,	  professor	  Erik	  Waage	  Nielsen	  also	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Staphylococcus	  aureus	  
Microbiology	  
Staphylococcus	  aureus	  is	  a	  Gram-­‐positive	  spherical	  bacterium	  growing	  in	  what	  
resembles	  golden	  grape	  clusters	  on	  blood	  agar,	  hence	  the	  name	  (21).	  The	  bacterium	  is	  
non-­‐motile,	  but	  can	  grow	  both	  aerobically	  and	  anaerobically	  in	  temperatures	  from	  18	  to	  
40	  degrees	  Celsius.	  It	  normally	  colonizes	  the	  anterior	  nares	  and	  perineum	  of	  humans	  
(22).	  It	  is	  a	  feared	  pathogen	  because	  of	  its	  increasingly	  wide	  antibiotic	  resistance	  and	  
coincidental	  ability	  to	  cause	  in-­‐hospital	  infections.	  These	  range	  from	  mere	  boils	  to	  lethal	  
septic	  shock	  (23).	  Structurally,	  S.	  aureus	  consists	  of	  a	  thick	  cellular	  wall	  of	  cross-­‐linked	  
peptidoglycan	  traversed	  by	  lipoteichoic	  acids	  (LTAs),	  covered	  by	  a	  polysaccharide	  
capsule.	  As	  in	  most	  Gram-­‐positive	  bacteria,	  half	  the	  cell	  wall	  weight	  consists	  of	  
peptidoglycan.	  Eleven	  different	  capsular	  serotypes	  have	  been	  discovered,	  but	  serotypes	  
5	  and	  8	  are	  the	  most	  frequently	  encountered	  in	  human	  infection	  (24).	  The	  capsule	  is	  
covered	  in	  biofilm,	  a	  loose	  water-­‐soluble	  slime	  layer.	  Both	  the	  capsule	  and	  slime	  layer	  
are	  permeated	  by	  a	  variety	  of	  surface	  proteins	  collectively	  termed	  microbial	  surface	  
components	  recognizing	  adhesive	  matrix	  molecules	  (MSCRAMMs).	  These	  facilitate	  
bacterial	  adhesion	  to	  host	  tissue	  (21).	  
Staphylococcus	  aureus	  infections	  
Staphylococcal	  infection	  is	  a	  dynamic	  process.	  Most	  of	  the	  MSCRAMMs	  are	  expressed	  
during	  the	  exponential	  growth	  phase.	  During	  this	  phase	  the	  bacteria	  aim	  at	  colonizing	  
and	  invading	  host	  tissue	  (23).	  Once	  colonization	  is	  achieved,	  the	  bacterium	  enters	  a	  
stationary	  phase	  where	  global	  regulatory	  genes	  switch	  to	  increased	  expression	  of	  
virulence	  factors.	  These	  facilitate	  spread	  within	  host	  and	  immune	  evasion	  (25).	  
Staphylococci	  usually	  infect	  the	  host	  through	  small	  breaches	  of	  the	  body's	  outermost	  
defense	  -­‐	  the	  skin.	  They	  gain	  access	  to	  underlying	  tissue	  and	  the	  blood	  stream	  through	  
wounds,	  invasive	  surgery	  or	  endovascular	  catheters.	  At	  this	  point	  the	  bacteria	  are	  
recognized	  and	  responded	  to	  -­‐	  confer	  the	  three	  R's	  in	  the	  introduction	  -­‐	  entailing	  a	  brisk	  
inflammatory	  response.	  Toxins	  also	  damage	  and	  expose	  endogenous	  DAMPs	  which	  
further	  potentiates	  this	  response.	  	  
Although	  beyond	  the	  scope	  of	  this	  review,	  Staphylococcus	  aureus	  quickly	  adapts	  to	  its	  
surroundings.	  The	  different	  mechanisms	  of	  antibiotic	  resistance	  obviously	  provide	  an	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advantage	  to	  survival,	  especially	  in	  communities	  with	  liberal	  antibiotic	  use.	  For	  further	  
reading,	  several	  reviews	  on	  the	  topic	  are	  available	  (26-­‐28).	  
Epidemiology	  
Staphylococcus	  aureus	  and	  especially	  methicillin-­‐resistant	  Staphylococcus	  aureus	  
(MRSA)	  is	  the	  leading	  cause	  of	  skin	  and	  soft	  tissue	  infections	  in	  the	  United	  States	  (29).	  
Not	  surprisingly,	  S.	  aureus	  is	  also	  a	  leading	  cause	  of	  invasive	  infection	  and	  sepsis	  
worldwide	  (30-­‐33).	  Incidence	  rates	  vary,	  but	  30	  cases	  per	  100	  000	  and	  a	  20	  per	  cent	  
mortality	  seems	  a	  fair	  estimate	  (34-­‐36).	  Needless	  to	  say,	  it	  is	  a	  serious	  and	  frequently	  
encountered	  pathogen.	  
The	  complement	  system	  
Introduction	  
The	  complement	  system	  is	  a	  group	  of	  over	  30	  different	  circulating	  and	  membrane-­‐
bound	  proteins	  rapidly	  activated	  in	  the	  vicinity	  of	  PAMPs	  and	  DAMPs.	  Next	  complement	  
also	  activates	  the	  adaptive	  immune	  system	  (37).	  In	  the	  beginning	  of	  complement	  system	  
research,	  the	  system	  was	  held	  to	  be	  "just	  an	  elegant	  model	  system"	  (38).	  As	  this	  research	  
has	  progressed,	  evidence	  suggests	  it	  an	  important	  system	  in	  immune	  surveillance	  and	  
therefore	  homeostasis	  -­‐	  It	  has	  several	  other	  functions	  beside	  that	  of	  antimicrobial	  
defense	  (39).	  There	  are	  nearly	  as	  many	  regulators	  in	  this	  system	  as	  there	  are	  effectors,	  
emphasizing	  that	  the	  system	  is	  highly	  potent	  and	  must	  be	  restrained.	  	  
The	  complement	  system	  has	  three	  different	  pathways	  of	  activation	  -­‐	  the	  classical	  
pathway	  (CP),	  lectin	  pathway	  (LP)	  and	  alternative	  pathway	  (AP).	  They	  all	  merge	  at	  the	  
formation	  of	  a	  C3	  convertase	  (Fig.	  2).	  The	  classical	  pathway,	  also	  known	  as	  the	  antibody-­‐
dependent	  pathway,	  is	  activated	  by	  IgM	  or	  IgG	  clusters	  -­‐	  hence	  the	  name,	  but	  also	  by	  
other	  pattern	  recognition	  molecules	  such	  as	  the	  pentraxins.	  After	  C1q	  binds,	  the	  two	  
pairs	  of	  serine	  proteases	  C1r	  and	  C1s	  activate	  each	  other	  reciprocally	  and	  the	  pentamer	  
C1	  splits.	  C1s	  further	  cleaves	  C4	  into	  C4a	  and	  C4b,	  the	  latter	  opsonizes	  the	  cell	  or	  
bacterium	  in	  question.	  C1s	  also	  cleaves	  C4-­‐bound	  C2	  into	  C2a	  and	  C2b	  in	  formation	  of	  
the	  classical	  and	  lectin	  pathway	  C3	  convertase,	  C4b2b.	  
The	  LP	  is	  similar	  to	  the	  CP	  ending	  in	  formation	  of	  the	  C4b2b.	  However,	  the	  initiating	  
danger	  signal	  and	  recognition	  molecules	  differ.	  Mannose-­‐binding	  lectin	  (MBL)	  and	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ficolins	  recognize	  mannose	  sugars	  on	  bacteria	  and	  IgA.	  Upon	  this	  activation,	  MBL	  and	  
ficolins	  associate	  with	  the	  MBL-­‐associated	  serine	  proteases	  (MASPs),	  notably	  MASP-­‐2	  
which	  then	  cleaves	  C4	  and	  C2	  (40).	  
The	  alternative	  pathway	  represents	  up	  to	  80-­‐90%	  of	  total	  complement	  activation	  (41).	  
The	  pathway	  is	  practically	  activated	  immediately	  as	  C3b	  is	  deposited	  on	  bacteria,	  
foreign	  or	  apoptotic	  cells	  owing	  to	  the	  constant	  tick-­‐over	  of	  C3;	  A	  small	  fraction	  of	  C3	  is	  
hydrolyzed	  to	  C3H2O	  which	  then	  binds	  factor	  B	  (FB).	  FB	  is	  subsequently	  cleaved	  by	  factor	  
D	  (FD)	  forming	  the	  C3	  convertase,	  C3H2OBb	  in	  plasma.	  This	  generates	  C3b	  with	  a	  
thioester	  moiety	  that	  binds	  amines	  and	  carbohydrates	  on	  foreign	  surfaces	  (39).	  An	  
initially	  modest	  tagging	  is	  then	  greatly	  amplified	  on	  foreign	  cells	  and	  inhibited	  on	  cells	  of	  
self	  by	  factor	  H	  (FH).	  Membrane-­‐bound	  C3b	  associates	  with	  FB	  which	  is	  then	  cleaved	  by	  
FD	  and	  the	  convertase	  further	  stabilized	  by	  properdin	  (FP),	  generating	  the	  AP	  C3	  
convertase,	  C3bBbP	  which	  then	  activates	  more	  C3	  for	  greater	  opsonization	  and	  
downstream	  complement	  activation.	  
As	  soon	  as	  AP	  amplification	  generates	  sufficient	  C3b	  the	  C3	  convertases	  also	  incorporate	  
C3	  (C4b2b3b	  or	  C3bBb3b)	  and	  shift	  their	  selectivity	  towards	  C5.	  C5	  is	  cleaved	  to	  C5a	  
and	  b.	  C5b	  can	  then	  bind	  C6	  through	  C8	  and	  several	  molecules	  of	  C9.	  This	  forms	  C5b-­‐9	  
also	  known	  as	  the	  membrane	  attack	  complex	  (MAC),	  which	  is	  able	  to	  punch	  holes	  in	  
lipid	  membranes	  and	  lyse	  microbes.	  Soluble	  C5b-­‐9	  (sC5b-­‐9)	  is	  also	  formed,	  and	  the	  two	  
forms	  of	  C5b-­‐9	  are	  collectively	  termed	  the	  terminal	  complement	  complex	  (TCC).	  
Complement	  in	  sepsis	  
The	  smaller	  fragments	  of	  complement	  activation,	  particularly	  C3a	  and	  C5a	  have	  
important	  functions	  in	  infection	  and	  inflammation	  (42).	  They	  are	  known	  as	  the	  
anaphylatoxins	  because	  of	  their	  ability	  to	  induce	  smooth	  muscle	  contraction	  and	  
capillary	  leakage.	  C5a	  is	  the	  more	  potent	  of	  the	  two.	  Through	  its	  two	  known	  receptors,	  
C5aR1	  and	  C5aR2,	  it	  functions	  as	  a	  powerful	  chemoattractant,	  activates	  phagocytic	  cells,	  
and	  induces	  the	  release	  of	  histamine,	  granule-­‐based	  enzymes	  and	  oxidants.	  C5a	  also	  
activates	  the	  coagulation	  system	  and	  impedes	  vasomotor	  control	  (43).	  
The	  complement	  system	  is	  dysregulated	  in	  sepsis	  and	  detectable	  anaphylatoxins	  and	  
TCC	  are	  proposed	  markers	  of	  complement	  hyperactivation	  (14).	  In	  this	  regard,	  C5a	  is	  
suggested	  the	  primary	  cause	  of	  the	  complement-­‐mediated	  effects:	  On	  the	  one	  hand	  high	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levels	  of	  C5a	  shut	  down	  many	  essential	  functions	  of	  the	  neutrophil	  such	  as	  chemotaxis	  
and	  oxidative	  burst.	  On	  the	  other	  hand	  C5a	  hyperactivates	  macrophages	  leading	  to	  
increased	  cytokine	  release	  (15,	  44).	  C5a	  also	  increases	  cytokine	  release	  from	  endothelial	  
cells	  alongside	  increased	  tissue	  factor	  (TF)	  expression.	  Lastly,	  high	  levels	  of	  C5a	  induce	  
thymocyte	  apoptosis	  and	  may	  contribute	  to	  the	  immunosuppression	  observed	  in	  late-­‐
stage	  sepsis.	  	  
Not	  surprisingly	  therefore,	  complement	  activation	  is	  often	  presented	  as	  a	  double-­‐edged	  
sword.	  An	  exaggerated	  heave	  harms	  the	  attacker	  just	  as	  much	  as	  the	  foe.	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Figure	  2:	  Overview	  of	  the	  complement	  system	  including	  the	  most	  common	  physiological	  inhibitors	  in	  red.	  CPN	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The	  complement	  system	  and	  Staphylococcus	  aureus	  
Staphylococcal	  interaction	  with	  the	  complement	  system	  is	  well	  studied	  over	  the	  last	  
decades.	  Obviously,	  the	  first	  studies	  examined	  the	  role	  of	  complement	  in	  
opsonophagocytosis.	  Later	  studies	  are	  discovering	  ever-­‐more	  intricate	  immune	  evasive	  
strategies	  of	  S.	  aureus.	  
Opsonization,	  phagocytosis	  and	  intracellular	  killing	  are	  essential	  steps	  in	  the	  process	  of	  
eradicating	  Staphylococcus	  aureus.	  Initial	  in	  vitro	  studies	  identified	  complement	  C2	  as	  an	  
essential	  factor	  of	  this	  process	  indicating	  CP	  and	  LP	  activation	  (45).	  Expressed	  
staphylococcal	  protein	  A	  (SpA)	  was	  shown	  to	  interfere	  with	  this	  activation	  by	  binding	  
the	  Fc-­‐portion	  of	  otherwise	  specific	  immunoglobulin	  G	  (IgG)	  thereby	  preventing	  
phagocytosis.	  However,	  in	  absence	  of	  IgG,	  complement	  activation,	  opsonization	  and	  
phagocytosis	  increased	  (46).	  Another	  unique	  study	  in	  C5	  deficient	  serum	  found	  no	  
significant	  importance	  of	  C5	  in	  opsonization	  and	  phagocytosis,	  indicating	  that	  other	  
opsonins	  are	  just	  as	  imporant	  in	  response	  to	  S.	  aureus	  (47).	  Peptidoglycan	  of	  the	  S.	  
aureus	  cell	  wall,	  but	  not	  teichoic	  acid,	  was	  proven	  the	  main	  activator	  and	  target	  of	  
complement	  opsonins.	  However,	  the	  opsonins	  were	  less	  efficient	  at	  triggering	  an	  innate	  
immune	  response	  to	  encapsulated	  S.	  aureus	  strains.	  C3	  was	  found	  deposited	  underneath	  
the	  capsule,	  hiding	  both	  peptidoglycan	  and	  C3	  from	  the	  complement	  receptors	  (48-­‐52).	  
The	  importance	  of	  both	  CP	  and	  AP	  activation	  in	  response	  to	  Staphylococcal	  
peptidoglycan	  were	  then	  confirmed.	  The	  other	  major	  cellular	  components	  teichoic	  acid,	  
lipoteichoic	  acid	  and	  protein	  A	  only	  activated	  complement	  via	  the	  CP	  (53-­‐54).	  
Complement	  activation,	  opsonization	  and	  phagocytosis	  were	  shown	  to	  increase	  further	  
with	  the	  use	  of	  some	  antibiotics.	  These	  interfered	  with	  staphylococcal	  protein	  synthesis	  
at	  subinhibitory	  concentrations	  (here	  clindamycin	  and	  doxycyclin).	  Antibiotics	  affecting	  
the	  cell	  wall	  (penicillin,	  cefotiam,	  piperacillin	  and	  vancomycin)	  did	  not	  help	  (55).	  
Additional	  studies	  showed	  a	  rapid	  degradation	  of	  C3b	  by	  factor	  I	  on	  S.	  aureus	  leaving	  
mere	  17%	  in	  the	  C3b	  state	  to	  continue	  AP	  activation	  (56).	  
The	  importance	  of	  complement	  activation	  in	  response	  to	  clinically	  relevant	  S.	  aureus	  
strains	  producing	  the	  capsule	  serotypes	  5	  and	  8	  was	  also	  confirmed	  in	  a	  murine	  model.	  
Sixty-­‐four	  percent	  of	  the	  C3	  depleted	  mice	  succumbed	  to	  a	  challenge	  of	  107	  CFU	  S.	  aureus,	  
compared	  to	  8%	  in	  the	  control	  group.	  Additionally,	  when	  the	  bacteria	  were	  in	  their	  mid-­‐
	   13	  
logarithmic	  phase,	  they	  bound	  10%	  as	  much	  C3	  compared	  to	  the	  stationary	  growth	  
phase,	  thus	  suggesting	  a	  direct	  relationship	  between	  capsule	  production	  and	  
complement	  evasion	  (57).	  These	  findings	  were	  reproduced	  by	  the	  same	  research	  group,	  
identifying	  C3	  and	  the	  complement	  receptor	  1	  (CR1,	  CD35),	  but	  not	  C5	  as	  essential	  in	  the	  
defense	  against	  S.	  aureus	  (58).	  However,	  in	  a	  more	  recent	  study	  C5a	  is	  proposed	  to	  have	  
a	  protective	  role.	  The	  C5-­‐knockout	  mouse	  strain	  showed	  significantly	  reduced	  survival	  
during	  staphylococcal	  bacteremia	  (59).	  
Although	  initially	  thought	  redundant	  in	  response	  to	  S.	  aureus,	  the	  LP	  of	  complement	  was	  
later	  found	  to	  increase	  C4b	  and	  iC3b	  deposition	  if	  MBL-­‐deficient	  sera	  were	  reconstituted	  
with	  purified	  MBL-­‐MASP	  (60).	  Furthermore,	  ficolin	  2	  of	  the	  LP	  was	  shown	  to	  recognize	  
lipoteichoic	  acid	  of	  S.	  aureus	  -­‐	  among	  other	  Gram-­‐positive	  species	  -­‐	  and	  activate	  
complement	  (61).	  However,	  MBL-­‐deficiency	  is	  common,	  and	  an	  interesting	  bypass	  of	  LP	  
activation	  through	  specific	  serum	  anti-­‐IgG	  recognizing	  IgG	  bound	  to	  wall	  teichoic	  acid	  
(WTA)	  was	  recently	  described	  (62).	  Thus,	  all	  complement	  pathways	  are	  involved	  in	  the	  
innate	  immune	  response	  towards	  S.	  aureus.	  
Staphylococcal	  components	  targeting	  complement	  	  
Willem	  and	  colleagues	  discovered	  several	  pathogenicity	  islands	  located	  on	  β-­‐hemolysin-­‐
converting	  bacteriophages	  that	  exchange	  important	  virulence	  factors	  between	  
staphylococci.	  These	  included	  the	  chemotaxis	  inhibitory	  protein	  of	  S.	  aureus	  (CHIPS),	  
staphylokinase	  (SAK),	  staphylococcal	  enterotoxin	  A	  (SEA)	  as	  well	  as	  the	  staphylococcal	  
complement	  inhibitor	  (SCIN),	  which	  all	  interfere	  with	  innate	  immune	  functions	  on	  
different	  levels	  (63).	  Accordingly,	  they	  termed	  the	  pathogenicity	  islands	  innate	  immune	  
evasion	  clusters	  (IECs).	  From	  these	  clusters,	  expressed	  SAK	  recruits	  and	  activates	  
plasminogen	  to	  plasmin	  on	  the	  bacterial	  surface	  where	  it	  then	  degrades	  human	  
immunoglobulin	  and	  C3b	  (64).	  SCIN,	  on	  the	  other	  hand,	  highly	  human	  specific	  and	  found	  
in	  90%	  of	  all	  S.	  aureus	  strains,	  binds,	  stabilizes,	  dimerizes	  and	  catalytically	  inactivates	  
the	  membrane-­‐bound	  C3	  convertases,	  thus	  inhibiting	  the	  main	  reactions	  of	  complement	  
activation	  (65,	  66).	  Other	  relevant	  virulence	  factors	  located	  on	  staphylococcal	  
pathogenicity	  islands	  include	  14	  staphylococcal	  superantigen-­‐like	  proteins	  (SSLs).	  The	  
seventh	  SSLs	  bind	  and	  inhibit	  C5	  activation	  (67)	  -­‐	  a	  feat	  potentiated	  by	  also	  binding	  IgA	  
(68).	  The	  tenth	  SSLs	  bind	  IgG	  preventing	  CP	  activation	  (69).	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Additional	  immune	  evasive	  virulence	  factors	  include	  the	  C3	  binding	  extracellular	  
fibrinogen-­‐binding	  protein	  (Efb)	  (70),	  the	  collagen-­‐binding	  MSCRAMMs,	  notably	  Cna,	  as	  
well	  as	  the	  SCIN	  homologues	  SCIN-­‐B	  and	  -­‐C	  and	  the	  Efb	  homologue,	  extracellular	  
complement-­‐binding	  protein	  (Ecb)	  (71).	  Cna	  and	  its	  related	  molecules	  are	  shown	  to	  
bind	  C1q,	  potentially	  interfering	  with	  CP	  activation	  (72).	  Staphylococcal	  Ecb	  is	  shown	  to	  
bind	  both	  C3	  and	  fibrinogen	  on	  its	  C	  and	  N	  termini,	  respectively,	  disrupting	  further	  
phagocytosis	  by	  neutrophils	  Obviously	  there	  is	  a	  bridge	  between	  the	  complement	  and	  
coagulation	  system	  in	  innate	  immune	  evasion	  (73).	  	  
Clumping	  factor	  A	  (ClfA),	  also	  involved	  with	  staphylococcal	  interaction	  with	  the	  
coagulation	  system	  (covered	  later),	  is	  shown	  to	  bind	  factor	  I	  and	  accelerate	  factor	  I-­‐
mediated	  decay	  of	  C3b	  (74,	  75).	  Secreted	  Staphylococcus	  aureus	  binder	  of	  IgG	  (Sbi)	  
forms	  a	  complex	  with	  factor	  H	  and	  C3b	  particles	  rendering	  the	  factor	  H	  moiety	  intact	  to	  
dampen	  complement	  activation	  together	  with	  factor	  I	  (76).	  Similarly,	  staphylococcal	  
iron-­‐regulated	  surface	  determinant	  protein	  (IsdH),	  expressed	  in	  milieus	  of	  low	  iron	  
concentrations,	  is	  suggested	  to	  reduce	  phagocytosis	  by	  converting	  C3b	  to	  iC3b	  (77).	  Also,	  
S.	  aureus	  is	  shown	  to	  recruit	  functionally	  active	  factor	  H	  to	  its	  surface	  to	  inhibit	  AP	  
activation	  and	  accelerate	  C3b	  inactivation	  (78).	  Staphylococcus	  aureus	  surface	  protein	  
(SdrE)	  is	  the	  proposed	  binding	  site	  for	  both	  factor	  H	  (79)	  and	  C4BP	  (80)	  -­‐	  thereby	  
interfering	  with	  all	  three	  pathways	  of	  complement	  activation,	  whereas	  Ecb	  has	  been	  
shown	  to	  increase	  this	  factor	  H	  acquisition	  to	  the	  bacterial	  surface	  (81).	  In	  this	  same	  
study	  factor	  H	  and	  Ecb	  are	  shown	  to	  mutually	  increase	  their	  C3b	  binding	  and	  ability	  to	  
inactivate	  complement	  activity.	  	  
Equally	  intriguing,	  secreted	  staphylococcal	  proteases	  are	  shown	  to	  inactivate	  
complement.	  The	  metalloprotease	  aureolysin	  cleaves	  C3	  into	  active	  C3a	  and	  C3b	  but	  
also	  recruits	  factors	  H	  and	  I	  ultimately	  resulting	  in	  quick	  C3	  inactivation	  (82).	  Another	  
study	  confirmed	  the	  effect	  of	  aureolysin,	  but	  also	  described	  anti-­‐complement	  activity	  of	  
three	  other	  staphylococcal	  proteases:	  the	  staphopains	  A	  and	  B	  and	  the	  serine	  protease	  
V8.	  They	  inhibit	  complement	  activation	  in	  general,	  and	  the	  LP	  in	  particular	  (83).	  
Interestingly,	  the	  authors	  also	  describe	  direct	  C5	  cleavage	  to	  active	  C5a	  by	  the	  proteases,	  
especially	  by	  aureolysin.	  However,	  they	  also	  indicate	  that	  this	  C5a	  is	  quickly	  degraded	  
further,	  minimizing	  actual	  complement	  activation.	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Thus,	  the	  list	  of	  interactions	  between	  staphylococci	  and	  the	  complement	  system	  seems	  
long	  and	  ever	  changing.	  Figure	  3	  provides	  a	  brief	  summary	  as	  of	  today.	  Perhaps	  
surprisingly,	  reports	  on	  the	  clinical	  relevance	  of	  the	  different	  complement	  interactions	  
are	  scarce.	  Although	  the	  murine	  models	  of	  staphylococcal	  bacteremia	  suggest	  
complement	  as	  an	  important	  defense	  mechanism,	  these	  findings	  will	  have	  to	  be	  further	  
evaluated	  in	  more	  complex	  animal	  models	  such	  as	  porcine	  models	  of	  sepsis.	  The	  first	  
observational	  study	  of	  S.	  aureus	  sepsis	  including	  complement	  analyses	  detected	  
ambiguous	  amounts	  of	  sC5b-­‐9	  in	  the	  patient	  samples,	  although	  this	  potentially	  should	  
reflect	  complement	  activation	  through	  all	  three	  pathways,	  no	  significant	  relationship	  
with	  patient	  outcome	  was	  found	  (84).	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Figure	  3:	  S.	  aureus	  versus	  the	  complement	  system.	  Staphylococcal	  virulence	  factors	  are	  indicated	  in	  red	  
whereas	  the	  physiological	  inhibitors	  are	  left	  out	  of	  this	  figure.	  SpA	  =	  Staphylococcal	  protein	  A,	  Sak	  =	  
Staphylokinase,	  ClfA	  =	  Clumping	  factor	  A,	  IsdH	  =	  Iron-­‐regulated	  surface	  determinant	  protein,	  SCIN	  =	  
Staphylococcal	  complement	  inhibitor,	  Sbi	  =	  Secreted	  Staphylococcus	  aureus	  binder	  of	  IgG,	  SdrE	  =	  
Staphylococcus	  aureus	  surface	  protein,	  Efb	  =	  Extracellular	  fibrinogen-­‐binding	  protein,	  Ecb	  =	  Extracellular	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The	  polymorphonuclear	  leukocytes	  and	  macrophages	  
Together	  with	  the	  complement	  system,	  the	  leukocytes	  serve	  as	  the	  first	  line	  of	  defense	  
against	  invasive	  bacterial	  disease.	  The	  polymorphonuclear	  neutrophils	  (PMNs),	  
monocytes	  and	  macrophages	  will	  be	  discussed	  in	  this	  review.	  
Polymorphonuclear	  neutrophils	  
Neutrophils	  are	  well-­‐reviewed,	  indispensable	  effectors	  of	  acute	  inflammation	  (85-­‐87).	  
They	  are	  the	  most	  abundant	  immune	  cell	  type,	  produced	  and	  stored	  in	  the	  bone	  marrow,	  
albeit	  with	  a	  continuous	  release	  to	  the	  circulation.	  There	  they	  readily	  await	  recruitment	  
to	  areas	  of	  inflammation	  through	  the	  fascinating	  process	  of	  tethering,	  rolling,	  adhesion,	  
crawling	  and	  transmigration	  (88),	  also	  beautifully	  illustrated	  in	  the	  first	  figure	  of	  ref.	  87.	  
This	  process	  is	  enabled	  by	  a	  multitude	  of	  chemoattractants,	  chemokines	  and	  homing	  
signals	  expressed	  on	  endothelium	  in	  response	  to	  infection	  and	  inflammation.	  Histamine,	  
arachidonic-­‐acid	  metabolites	  and	  diverse	  cytokines	  induce	  the	  expression	  of	  selectins	  
(types	  P	  and	  E,	  in	  particular)	  and	  integrins	  (such	  as	  the	  intracellular	  adhesion	  molecules,	  
ICAMs	  and	  the	  vascular	  cell	  adhesion	  proteins,	  VCAMs).	  These	  bind	  neutrophils	  to	  the	  
lumen	  surface.	  Simultaneously,	  the	  neutrophils	  are	  activated	  in	  two-­‐step	  process	  by	  
exposure	  to	  pro-­‐inflammatory	  cytokines	  such	  as	  TNF	  and	  interleukin	  (IL-­‐)	  1-­‐β	  and	  
recognition	  of	  PAMPs,	  chemoattractants	  -­‐	  particularly	  IL-­‐8	  -­‐	  or	  growth	  factors.	  
Neutrophil	  activation	  through	  G-­‐coupled	  chemokine	  receptors	  induces	  conformational	  
changes	  in	  expressed	  integrin	  receptors,	  including	  CD11a-­‐CD18	  and	  CD11b-­‐CD18	  
thereby	  facilitating	  neutrophil	  adhesion	  to	  the	  endothelium.	  When	  at	  the	  endothelial	  
surface,	  bound	  neutrophils	  crawl	  and	  search	  for	  the	  optimal	  portal	  of	  entry	  to	  the	  
peripheral	  tissues.	  The	  actual	  transmigration	  or	  diapedisis	  is	  either	  paracellular	  or	  
transcellular,	  and	  enabled	  through	  interaction	  with	  the	  integrins.	  
Once	  the	  neutrophils	  have	  entered	  the	  peripheral	  tissues,	  they	  migrate	  along	  a	  
chemokine	  trail	  to	  the	  focus	  of	  inflammation.	  The	  chemoattractants	  are	  either	  
"intermediate"	  or	  "end-­‐target"	  meaning	  that	  the	  intermediate	  chemokines	  such	  as	  IL-­‐8	  
and	  leukotriene	  B4	  (LTB4)	  have	  less	  effect	  on	  chemotaxis	  than	  the	  end-­‐stage	  
chemokines,	  such	  as	  C5a	  and	  bacteria-­‐derived	  N-­‐fomyl-­‐methionyl-­‐leucil-­‐phenylalanine	  
(fMLP),	  which	  are	  in	  abundance	  close	  to	  the	  focus	  of	  inflammation.	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Activated	  neutrophils	  have	  several	  potent	  mechanisms	  to	  fight	  and	  kill	  pathogens.	  
Opsonization,	  as	  described	  earlier,	  enables	  phagocytosis	  of	  cells	  and	  organisms	  with	  
PAMPs	  or	  DAMPs	  through	  the	  activation	  of	  complement-­‐	  or	  immunoglobulin-­‐receptors.	  
The	  incorporated	  phagosome	  is	  then	  brutally	  flooded	  with	  either	  reactive	  oxygen	  
species	  (ROS)	  or	  antibacterial	  proteins	  such	  as	  cathepsins,	  defensins,	  lactoferrin	  and	  
lysozyme	  as	  the	  granules	  containing	  these	  effectors	  fuse	  with	  the	  phagosome	  (89).	  The	  
granules	  containing	  antibacterial	  proteins	  can	  also	  be	  expelled	  to	  attack	  extracellular	  
pathogens.	  Additionally,	  neutrophils	  have	  recently	  been	  shown	  to	  degrade	  their	  DNA	  
and	  incorporate	  it	  with	  histones,	  proteins	  (lactoferrin	  and	  cathepsin	  to	  name	  a	  few)	  and	  
enzymes	  (such	  as	  myeloperoxidase	  (MPO)	  and	  elastase)	  for	  release	  to	  the	  extracellular	  
milieu	  as	  neutrophil	  extracellular	  traps	  (NETs)	  (90).	  As	  the	  name	  implies,	  these	  engulf	  
and	  stop	  pathogen	  spread,	  facilitate	  phagocytosis	  and	  possibly	  kill	  the	  pathogen	  directly	  
with	  the	  associated	  antimicrobial	  histones	  and	  proteases.	  
Importantly,	  activated	  neutrophils	  have	  the	  ability	  to	  recruit	  and	  activate	  more	  
neutrophils	  in	  a	  positive-­‐feedback	  fashion	  during	  infection	  and	  inflammation	  (86).	  
Monocytes	  and	  macrophages	  
Monocytes	  constitute	  another	  group	  of	  important	  innate	  immune	  cells.	  They	  have	  both	  
intravascular	  effector	  functions	  of	  their	  own	  (91)	  and	  serve	  as	  myeloid	  precursors	  of	  the	  
tissue-­‐resident	  macrophages	  and	  dendritic	  cells,	  collectively	  termed	  MDPs	  (92).	  Based	  
on	  their	  cell-­‐surface	  expression	  of	  chemokine	  receptors,	  CD14	  and	  CD16,	  monocytes	  are	  
divided	  into	  two	  main	  subsets:	  CD14highCD16-­‐	  or	  CD14lowCD16+,	  also	  known	  as	  CD14+	  
and	  CD16+	  cells,	  respectively	  (93).	  The	  former	  represents	  80-­‐90%	  of	  circulating	  
monocytes	  and	  exerts	  a	  dominantly	  anti-­‐inflammatory	  cytokine	  profile	  dominated	  by	  IL-­‐
10	  in	  response	  to	  LPS	  in	  vitro.	  The	  CD16+	  cells	  on	  the	  other	  hand,	  accounting	  for	  about	  
10%	  of	  the	  circulating	  monocytes,	  express	  TNF	  and	  IL-­‐1	  in	  response	  to	  LPS	  and	  are	  
accordingly	  termed	  pro-­‐inflammatory.	  The	  number	  of	  CD16+	  cells	  increase	  during	  
infection	  (94).	  
Similar	  to	  neutrophils,	  monocytes	  are	  recruited	  by	  chemokines	  (95).	  CC-­‐chemokine	  
ligand	  2	  (CCL2)	  is	  expressed	  by	  a	  variety	  of	  cells	  activated	  by	  cytokines,	  PAMPs	  or	  
DAMPs.	  CCL2	  binds	  to	  the	  CC-­‐chemokine	  receptor	  2	  (CCR2)	  expressed	  in	  high	  amounts	  
on	  the	  CD14+	  monocytes.	  Other	  chemokines	  also	  home	  monocytes	  to	  the	  vessel	  wall,	  
where	  they	  bind	  and	  transmigrate	  by	  aid	  of	  selectins	  and	  integrins.	  This	  way,	  depending	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on	  the	  chemokines,	  monocytes	  replenish	  different	  tissue-­‐resident	  macrophages,	  such	  as	  
osteoclasts,	  alveolar	  macrophages	  and	  Kuppfer	  cells	  (96)	  
Circulating	  monocytes	  are	  competent	  phagocytes.	  They	  can	  destroy	  pathogens	  using	  
phagolysosomal	  enzymes	  or	  through	  the	  release	  of	  reactive	  nitrogen	  and	  oxygen	  species	  
(93).	  Additionally,	  pathogens	  recognized	  by	  monocytes	  induce	  cytokine	  responses	  to	  
alert	  and	  activate	  other	  components	  of	  the	  innate	  immune	  system.	  Particularly,	  
monocytes	  are	  shown	  to	  differentiate	  into	  TNF-­‐	  and	  inducible	  nitric	  oxide	  syntethase	  
(iNOS)	  producing	  (TIP)	  cells.	  These	  cells	  expel	  CC-­‐chemokine	  ligands	  2	  and	  7	  (CCL2	  and	  
7)	  necessary	  for	  sufficient	  monocyte	  recruitment	  in	  response	  to	  bacterial	  infection.	  
Toll-­‐like	  receptors	  
Importantly,	  both	  neutrophils	  and	  monocytes	  express	  Toll-­‐like	  receptors	  (TLRs)	  
essential	  for	  especially	  PAMP,	  but	  also	  DAMP	  recognition	  (97,	  98).	  These	  are	  the	  best-­‐
studied	  pattern	  recognition	  receptors	  or	  molecules	  (PRRs)	  of	  the	  innate	  immune	  system	  	  
(99,	  100).	  PRRs	  recognize	  a	  multitude	  of	  structures	  considered	  dangerous	  or	  foreign	  to	  
the	  host.	  These	  structures	  include	  essential,	  conserved	  microbial	  structures	  (PAMPs),	  e.g.	  
the	  lipid	  A-­‐portion	  of	  LPS	  in	  Gram-­‐negative	  bacteria	  and	  peptidoglycan	  of	  Gram-­‐positive	  
bacteria	  (101).	  
To	  date,	  10	  different	  human	  TLRs	  are	  known.	  These	  are	  transmembrane	  proteins	  of	  
either	  the	  cell	  wall	  or	  intracellular	  compartments,	  characterized	  by	  their	  extracellular	  
leucine-­‐rich	  repeat	  (LRR)	  domains	  and	  intracellular	  Toll/IL-­‐1	  receptor	  (TIR)	  domains.	  
TLR4	  was	  the	  first	  receptor	  described	  and	  recognizes	  LPS	  whereas	  TLR2	  is	  found	  to	  
recognize	  a	  broad	  range	  of	  PAMPs	  through	  its	  association	  with	  either	  TLR1	  or	  TLR6.	  
Notably,	  several	  accessory	  molecules	  to	  the	  TLRs	  are	  described,	  such	  as	  CD14,	  essential	  
to	  not	  only	  proper	  LPS	  recognition	  but	  cofactor	  to	  several	  other	  TLRs	  as	  well,	  such	  as	  
those	  recognizing	  peptidoglycan	  and	  bacterial	  DNA	  (102).	  
TLR	  activation	  results	  in	  downstream	  signaling	  events	  culminating	  in	  increased	  
expression	  of	  cytokines,	  chemokines,	  major	  histocompatibility	  complexes	  (MHCs)	  and	  
co-­‐stimulatory	  molecules	  as	  well	  as	  cell-­‐specific	  activation	  such	  as	  increased	  ROS	  
production	  and	  phagocytic	  activity	  in	  neutrophils.	  The	  MyD88-­‐dependent	  pathway	  
resulting	  in	  phosphorylation	  and	  subsequent	  activation	  of	  nuclear	  factor	  kappa	  B	  (NF-­‐
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kappa-­‐B)	  is	  generally	  the	  most	  known.	  It	  is	  presumably	  the	  most	  important	  in	  the	  
cellular	  innate	  immune	  response	  (103).	  
	  
Figure	  4:	  Overview	  of	  PMN,	  monocyte	  and	  macrophage	  effector	  functions.	  
PMNs,	  monocytes,	  TLRs	  and	  sepsis	  
In	  sepsis,	  neutrophil	  and	  monocyte	  function	  and	  recruitment	  is	  disrupted	  (104,	  105).	  
Higher	  levels	  of	  chemokines	  in	  plasma,	  compared	  to	  a	  single	  foci	  of	  infection,	  
downregulate	  chemokine	  receptors.	  High	  levels	  of	  cytokines	  from	  various	  immune	  cells,	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Altered	  TLR	  signaling	  is	  an	  important	  cause	  of	  the	  altered	  leukocyte	  functions	  seen	  in	  
sepsis	  (106).	  Interestingly,	  monocytes	  and	  neutrophils	  are	  shown	  to	  respond	  differently	  
in	  sepsis	  according	  to	  the	  disease	  severity.	  Cells	  isolated	  in	  the	  early	  phases	  of	  disease	  
are	  generally	  hyperresponsive	  to	  PAMPs	  and	  thus	  highly	  pro-­‐inflammatory	  whereas	  
cells	  isolated	  in	  the	  later	  stages	  of	  disease	  (severe	  sepsis	  and	  septic	  shock)	  were	  
hyporesponsive	  and	  more	  anti-­‐inflammatory	  in	  nature	  (107).	  
Staphylococcal	  interaction	  with	  PMNs	  and	  monocytes	  
There	  are	  numerous	  documented	  interactions	  between	  Staphylococcus	  aureus	  and	  the	  
neutrophils,	  monocytes	  and	  their	  TLRs	  (as	  summarized	  in	  figure	  5	  at	  the	  end	  of	  this	  
section).	  These	  include	  the	  opsonophagocytosis	  of	  S.	  aureus	  by	  leukocytes,	  the	  effects	  of	  
various	  staphylococcal	  virulence	  factors	  on	  leukocytes	  as	  well	  as	  specific	  staphylococcal	  
TLR	  interactions.	  Equally,	  several	  recent	  reports	  on	  NET	  formation	  in	  response	  to	  S.	  
aureus	  have	  been	  published	  recently.	  
Opsonophagocytosis	  
As	  mentioned,	  opsonophagocytosis	  of	  S.	  aureus	  is	  the	  primary	  way	  of	  eradicating	  the	  
pathogen.	  This	  process	  is	  initiated	  by	  opsonins	  such	  as	  the	  complement	  system,	  and	  
completed	  by	  the	  phagocytes,	  neutrophils	  and	  monocytes.	  One	  early	  study	  concluded	  
that	  neutrophils	  were	  better	  at	  phagocytosis	  of	  S.	  aureus	  than	  monocytes,	  and	  that	  
neutrophils	  could	  ingest	  roughly	  230	  bacteria	  per	  cell,	  and	  kill	  close	  to	  90%	  of	  these	  
within	  the	  20	  minute	  time-­‐frame	  (108).	  For	  monocytes,	  the	  corresponding	  numbers	  
were	  50	  bacteria	  and	  40%,	  respectively.	  The	  bacteria	  were,	  however,	  pre-­‐opsonized	  in	  
5%	  serum,	  but	  a	  threshold	  for	  phagocytosis	  was	  documented.	  Further	  studies	  of	  
bacterial	  uptake	  kinetics	  confirmed	  the	  threshold	  using	  flow	  cytometry.	  In	  general,	  
leukocytes	  could	  maximally	  collect	  about	  80	  bacteria,	  eat	  45	  and	  kill	  40	  (109).	  The	  
process	  of	  bacterial	  uptake	  was	  also	  confirmed	  accelerated	  by	  opsonins	  and	  an	  
endothelial	  cell	  surface,	  in	  a	  later	  study,	  also	  showing	  that	  opsonization	  was	  unrelated	  to	  
metabolic	  activity,	  oxidative	  burst	  and	  degranulation	  by	  phagocytes	  (110,	  111).	  In	  fact,	  
complement-­‐opsonized	  S.	  aureus	  were	  shown	  to	  induce	  neutrophil	  aggregation	  or	  
clumping,	  i.e.	  a	  sign	  of	  neutrophil	  hyperactivation	  (112).	  Increased	  CD66b	  was	  later	  
identified	  as	  an	  important	  mediator	  of	  this	  neutrophil	  aggregation	  during	  sepsis	  (113).	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Concerning	  phagocyte	  recruitment,	  formylated	  peptides	  were	  identified	  as	  crucial	  
chemoattractants,	  but	  not	  the	  only	  ones	  as	  bacteria	  unable	  to	  produce	  the	  peptides	  still	  
recruited	  neutrophils,	  albeit	  at	  a	  much	  lower	  rate	  (114).	  Phenol-­‐soluble	  modulin	  (PSM),	  
a	  staphylococcal	  exotoxin,	  was	  recently	  identified	  as	  a	  potent	  stimulator	  of	  formyl	  
peptide	  receptor	  2	  on	  neutrophils	  (115).	  LTA	  (116),	  peptidoglycan	  (117)	  and	  
staphylococcal	  lipase	  (118)	  are	  other	  proposed	  chemoattractants,	  but	  at	  least	  
peptidoglycan	  recruits	  neutrophil	  through	  complement	  activation.	  Recently,	  
perivascular	  macrophages	  were	  identified	  as	  an	  important	  source	  of	  neutrophil	  
chemoattractants	  during	  staphylococcal	  skin	  infection,	  but	  that	  they	  consequently	  were	  
a	  target	  for	  S.	  aureus	  α-­‐toxin,	  which	  also	  lyses	  the	  macrophages	  and	  reduced	  neutrophil	  
recruitment	  (119).	  
Even	  so,	  following	  ingestion	  of	  S.	  aureus,	  neutrophils	  release	  LTB4	  (120).	  Thereby	  they	  
recruit	  more	  neutrophils,	  and	  increase	  their	  expression	  of	  complement	  receptor	  3	  
(CD11b-­‐CD18)	  to	  further	  increase	  their	  capacity	  to	  ingest	  bacteria	  (121).	  Neutrophils	  
then	  use	  ROS	  to	  kill	  the	  pathogen.	  NADPH	  oxidase	  and	  to	  a	  lesser	  extent	  
myeloperoxidase	  (MPO)	  generates	  oxygen	  radicals,	  acting	  in	  concert	  for	  optimal	  effect	  
(122).	  This	  generation	  of	  ROS	  also	  proved	  dependent	  on	  increased	  intracellular	  calcium	  
(123).	  Lysosomal	  cathepsin	  G,	  a	  cationic	  antimicrobial	  protein	  possibly	  binding	  WTA	  
was	  identified	  as	  a	  non-­‐oxidative	  S.	  aureus	  bactericide,	  albeit	  at	  a	  limited	  7.5	  pH	  interval	  
(124).	  Equally,	  phospholipase	  A2	  contributes	  to	  staphylococcal	  degradation	  in	  concert	  
with	  ROS	  generation	  (125).	  Furthermore,	  neutrophils	  are	  now	  known	  to	  secrete	  
calprotectin	  chelating	  the	  micronutrients	  manganese	  and	  zinc	  to	  restrict	  staphylococcal	  
growth	  within	  abscesses	  (126).	  The	  two	  trace	  elements	  were	  later	  proved	  essential	  in	  
staphylococcal	  superoxide	  defense	  by	  interfering	  with	  the	  superoxide	  dismutase	  (127).	  
Likewise,	  iron-­‐depleted	  staphylococci	  were	  rendered	  more	  vulnerable	  to	  phagocytosis	  
and	  killing	  (128)	  and	  microarray-­‐studies	  of	  staphylococci	  suffering	  from	  oxidative	  stress	  
were	  shown	  to	  upregulate	  genes	  related	  to	  iron	  and	  heme	  uptake,	  with	  decreased	  
resistance	  to	  oxidation	  if	  they	  were	  stripped	  of	  these	  genes	  (129).	  In	  return,	  too	  much	  
iron	  was	  also	  shown	  to	  increase	  ROS-­‐mediated	  killing	  of	  staphylococci	  by	  monocytes	  
(130).	  
However,	  killing	  of	  S.	  aureus	  turned	  out	  more	  laborious	  than	  with	  other	  bacteria,	  first	  
reflected	  in	  increased	  energy	  expenditure	  by	  neutrophils	  after	  ingestion	  of	  S.	  aureus	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(131).	  Later	  S.	  aureus	  was	  shown	  to	  survive	  inside	  neutrophils	  (132),	  and	  exploit	  them	  
to	  spread	  within	  the	  host	  -­‐	  a	  notion	  recently	  reviewed	  (133).	  In	  fact,	  S.	  aureus	  was	  first	  
shown	  to	  promote	  neutrophil	  apoptosis	  (134),	  later	  defined	  as	  phagocytosis-­‐induced	  
cell	  death	  (PCID),	  a	  general	  neutrophil	  response	  to	  several	  ingested	  pathogens	  in	  the	  
aim	  of	  resolution,	  but	  S.	  aureus	  it	  seems,	  has	  found	  a	  way	  to	  circumvent	  apoptosis,	  rather	  
inducing	  necrosis	  and	  lysis	  of	  the	  neutrophil	  and	  ensuring	  its	  own	  escape	  and	  survival	  
(135).	  Indeed,	  a	  large	  microarray	  of	  staphylococcal	  genes	  in	  contact	  with	  neutrophils	  
revealed	  upregulation	  of	  several	  genes	  involved	  in	  immune	  evasion,	  protection	  from	  
phagocytosis	  and	  enhanced	  virulence	  (136).	  
Staphylococcal	  virulence	  factors	  targeting	  neutrophils	  and	  monocytes	  
Staphylococcal	  α-­‐toxin,	  initially	  identified	  as	  a	  hemolysin,	  was	  shown	  to	  prime	  
neutrophils	  at	  low	  concentrations	  (10	  hemolytic	  units),	  and	  damage	  them	  at	  higher	  
concentrations	  (137).	  Compared	  to	  strains	  lacking	  toxin	  production,	  strains	  with	  α-­‐toxin	  
were	  shown	  to	  significantly	  increase	  neutrophil	  count	  and	  enhance	  virulence	  in	  a	  
murine	  model	  of	  pneumonia	  (138).	  A	  similar	  priming	  effect	  was	  observed	  with	  TNF,	  but	  
ingested	  staphylococci	  manage	  to	  downregulate	  TNF-­‐receptors	  on	  neutrophils	  thereby	  
reducing	  their	  bactericidal	  capacity	  (139).	  Staphylococcal	  δ-­‐toxin	  was	  also	  shown	  to	  
prime	  neutrophils	  in	  combination	  with	  either	  TNF	  or	  LPS,	  and	  induced	  TNF	  release	  and	  
CR3	  expression	  directly	  (140).	  Staphylococcal	  enterotoxins	  A	  and	  B	  were	  shown	  to	  
reduce	  neutrophil	  apoptosis	  and	  increase	  phagocyte	  receptor	  Fc-­‐gamma	  expression	  
through	  T-­‐cell	  and	  monocyte	  activation	  (141).	  Enterotoxin	  A	  was	  later	  identified	  to	  
protect	  S.	  aureus	  from	  neutrophil	  killing	  (142).	  Equally,	  a	  protein	  in	  the	  staphylococcal	  
supernate,	  later	  identified	  as	  CHIPS	  (143),	  managed	  to	  downregulate	  chemokine	  
receptors	  for	  C5a	  and	  formylated	  peptides	  significantly	  reducing	  chemotaxis	  to	  these	  
two	  chemokines,	  but	  not	  IL-­‐8	  (144).	  However,	  high	  levels	  of	  TNF	  during	  staphylococcal	  
sepsis	  were	  suggested	  to	  downregulate	  IL-­‐8	  receptors	  as	  well	  (145).	  Staphylococcal	  β-­‐
hemolysin,	  also	  known	  as	  β-­‐toxin,	  was	  shown	  to	  directly	  downregulate	  IL-­‐8	  production	  
in	  endothelial	  cells	  (146).	  In	  the	  same	  regard,	  staphylococcal	  extracellular	  adherence	  
protein	  (Eap)	  was	  shown	  to	  restrict	  neutrophil	  interaction	  with	  endothelium,	  thereby	  
further	  limiting	  recruitment	  (147).	  This	  was	  also	  true	  for	  the	  staphylococcal	  
superantigen-­‐like	  protein	  5	  (SSL-­‐5)	  binding	  P-­‐selectin	  glycoprotein	  ligand	  1	  (PSGL-­‐1).	  
This	  prevents	  neutrophil	  interaction	  with	  P-­‐selectin	  and	  consequently	  its	  rolling	  along	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the	  endothelium	  during	  neutrophil	  recruitment	  (148).	  In	  fact,	  SSL-­‐5	  was	  shown	  to	  
inhibit	  neutrophil	  activation	  by	  all	  chemokines	  and	  anaphylatoxins	  and	  thus	  a	  large	  
portion	  of	  the	  chemoattractants.	  First,	  SSL-­‐5	  binds	  to	  the	  receptors	  of	  the	  various	  
chemokine	  and	  anaphylatoxin	  receptors.	  Second,	  SSL-­‐5	  scavenges	  the	  surrounding	  
milieu	  for	  the	  actual	  chemokines	  and	  anaphylatoxins	  themselves,	  and	  pin	  them	  to	  the	  
neutrophil	  surface	  (149).	  Also,	  D-­‐alanine	  modification	  of	  staphylococcal	  LTA	  and	  WTA	  
yielded	  resistance	  to	  phospholipase	  A2-­‐mediated	  degradation	  of	  S.	  aureus	  (150)	  and	  
reduced	  staphylococcal	  virulence	  in	  mice	  if	  missing	  (151).	  
Yet	  another	  staphylococcal	  exotoxin	  was	  proposed	  as	  an	  inductor	  of	  neutrophil	  
apoptosis	  through	  a	  p38-­‐mitogen-­‐activated-­‐kinase	  mechanism	  (152).	  Staphylococcal	  
serine	  protease	  staphopain	  B	  (Sspb)	  was	  identified	  as	  such	  a	  factor.	  Although	  apparently	  
unrelated	  to	  the	  p38-­‐pathway,	  this	  serine	  protease	  is	  proposed	  to	  cleave	  CD11b	  on	  the	  
surface	  of	  neutrophils	  and	  monocytes	  inducing	  a	  form	  of	  apoptosis	  or	  necrosis	  (153).	  
Interestingly,	  IgG	  protected	  the	  cells	  from	  SspB-­‐induced	  cell	  death,	  but	  staphylococcal	  
protein	  A	  (Spa),	  binding	  the	  Fc-­‐fragment	  of	  IgG	  with	  high	  affinity,	  restored	  the	  
detrimental	  effect	  of	  SspB.	  Two	  other	  important	  functions	  of	  Spa	  were	  elucidated.	  First,	  
Spa	  was	  shown	  to	  activate	  the	  TNF-­‐receptor	  and	  increase	  IL-­‐8	  secretion	  in	  pulmonary	  
epithelium	  (154).	  Second,	  Spa	  was	  shown	  to	  exert	  additive	  action	  with	  Panton	  Valentine	  
Leukocidin	  (PVL)	  in	  the	  pathogenesis	  of	  lethal	  necrotizing	  pneumonia	  (155).	  PVL	  is	  a	  
pore-­‐forming	  bi-­‐component	  cytotoxic	  factor	  of	  neutrophils	  consisting	  of	  components	  F	  
(lukF-­‐PV)	  and	  S	  (lukS-­‐PV)	  that	  insert	  into	  the	  plasma	  membrane	  and	  lyse	  cells,	  and	  
especially	  human	  neutrophils	  (156).	  Spa	  and	  PVL	  were	  identified	  as	  major	  contributors	  
to	  the	  lung	  injury	  in	  the	  necrotizing	  pneumonia	  through	  recruiting	  and	  lysing	  
neutrophils,	  respectively	  (157).	  Additionally,	  staphopain	  A	  (Sspa)	  was	  shown	  to	  degrade	  
pulmonary	  surfactant	  protein	  A,	  an	  alveolar	  collectin,	  thus	  potentially	  increasing	  
pulmonary	  virulence	  further	  (158).	  
Staphylococcal	  neurotoxins	  
Notably,	  PVL	  is	  one	  of	  few	  virulence	  factors	  often	  expressed	  in	  community-­‐associated	  
MRSA	  strains	  (159).	  Following	  its	  discovery	  in	  disease,	  several	  other	  potential	  leukocyte	  
cytotoxins	  (leukocidins)	  were	  studied.	  Phenol-­‐soluble	  modulin	  alpha	  3	  (PSM	  alpha	  3)	  
turned	  out	  to	  cause	  neutrophil	  lysis	  in	  vitro,	  but	  its	  true	  potency	  was	  in	  its	  synergistic	  
effect	  in	  combination	  with	  PVL	  (160).	  Furthermore,	  PSMs	  were	  shown	  to	  activate	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neutrophils	  via	  the	  formyl	  peptide	  receptor	  2	  (FPR2)	  thereby	  increasing	  oxidative	  burst	  
which	  inactivates	  PSMs.	  In	  this	  regard	  PSMs	  ultimately	  trigger	  their	  own	  inactivation.	  
However,	  PSMs	  also	  render	  the	  neutrophils	  insensitive	  to	  other	  stimuli	  and	  prone	  to	  
initiate	  apoptosis	  through	  another	  pathway	  not	  yet	  distinguished	  (161).	  The	  effect	  of	  
particularly	  PSM-­‐α	  peptides	  on	  neutrophil	  lysis	  following	  phagocytosis	  was	  confirmed	  in	  
another	  study,	  showing	  that	  function	  of	  the	  PSM-­‐α-­‐operon	  alone	  was	  sufficient	  for	  
increased	  neutrophil	  lysis	  and	  consequent	  staphylococcal	  survival	  (162).	  Yet	  another	  
member	  of	  the	  pore-­‐forming	  leukotoxin	  family,	  LukAB,	  was	  recently	  shown	  to	  
specifically	  target	  CD11b	  of	  the	  integrin	  Mac-­‐1/CR3	  (163).	  As	  mentioned	  previously,	  
CR3	  is	  upregulated	  in	  response	  to	  S.	  aureus	  and	  the	  investigators	  show	  that	  this	  is	  
necessary	  for	  LukAB	  cytotoxicity,	  thus	  it	  only	  targets	  S.	  aureus-­‐activated	  neutrophils.	  
Likewise,	  PVL	  was	  shown	  to	  target	  the	  two	  C5a	  receptors,	  not	  only	  lysing	  the	  cells	  but	  
also	  halting	  C5a-­‐induced	  immune	  responses	  (164).	  However,	  in	  sublytic	  concentrations,	  
PVL	  is	  also	  shown	  to	  prime	  neutrophils	  and	  increase	  their	  ability	  to	  kill	  staphylococci	  
(165).	  
S.	  aureus	  is	  actually	  documented	  to	  release	  five	  different	  bi-­‐component	  leukotoxins.	  In	  
addition	  to	  PVL	  and	  LukAB,	  LukED,	  HlgAB	  and	  HlgCB	  have	  been	  described	  (166).	  LukED	  
concentrations	  were	  recently	  shown	  to	  stimulate	  neutrophils	  in	  a	  dose-­‐dependent	  
manner	  at	  nanomolar	  concentrations	  in	  vitro	  (167).	  Furthermore,	  both	  PVL	  (168)	  and	  
LukAB	  (169)	  are	  now	  documented	  NET	  inducers.	  But	  it	  seems	  S.	  aureus	  has	  developed	  
evasive	  mechanisms	  to	  NETs	  through	  the	  release	  of	  nuclease	  (170)	  and	  adenosine	  
synthase,	  which	  degrade	  NETs.	  The	  resulting	  deoxyadenosine	  induces	  caspase-­‐3-­‐
mediated	  macrophage	  apoptosis	  (171).	  
Global	  regulatory	  genes	  
As	  mentioned,	  global	  regulatory	  genes	  control	  the	  expression	  of	  staphylococcal	  
virulence	  factors.	  Of	  these,	  the	  agr	  operon	  is	  the	  most	  extensively	  studied,	  showing	  that	  
staphylococci	  in	  sufficient	  densities	  activate	  a	  system	  where	  they	  use	  small	  peptides	  to	  
communicate	  and	  activate	  these	  genes	  by	  increasing	  RNAIII	  expression.	  This	  is	  known	  
as	  quorum	  sensing.	  One	  study	  documented	  increased	  activity	  in	  the	  agr	  quorum-­‐sensing	  
system	  by	  measuring	  the	  increased	  amounts	  of	  α-­‐toxin	  and	  increased	  neutrophil	  lysis	  in	  
response	  to	  phagocytosis	  (172).	  Another	  saw	  reduced	  release	  of	  phenol-­‐soluble	  
modulins	  and	  consequently	  reduced	  activation	  of	  neutrophils	  by	  this	  PAMP	  (173).	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Biofilms	  
S.	  aureus	  also	  produce	  a	  protective	  biofilm	  on	  non-­‐organic	  surfaces,	  but	  phagocytes	  are	  
shown	  to	  activate,	  penetrate	  and	  to	  ingest	  bacteria	  despite	  of	  this	  (174-­‐176).	  Indeed,	  
staphylococcal	  biofilms	  have	  been	  considered	  a	  more	  potent	  virulence	  factor	  in	  S.	  
epidermidis,	  which	  are	  also	  shown	  to	  protect	  themselves	  form	  neutrophil	  recognition	  
and	  phagocytosis	  to	  a	  greater	  extent	  than	  S.	  aureus	  (177).	  Additionally,	  oxidative	  burst	  
by	  phagocytes	  in	  response	  to	  biofilm	  was	  increased	  through	  preopsonization	  with	  IgG	  
and	  C3b,	  but	  neutrophil	  adhesion	  was	  unaltered	  either	  way	  (178).	  Nanovesicles	  
produced	  by	  neutrophils	  were	  shown	  to	  inhibit	  biofilm	  formation	  in	  S.	  epidermidis	  but	  
not	  S.	  aureus	  (179).	  An	  analysis	  of	  the	  S.	  aureus	  transcriptome	  in	  response	  to	  phagocytes	  
showed	  a	  significant	  downregulation	  of	  factors	  for	  growth,	  indicating	  a	  form	  of	  
hibernation	  inside	  the	  biofilms	  if	  necessary	  (180).	  
Effects	  of	  antimicrobials	  on	  opsonophagocytosis	  
The	  effects	  of	  different	  drugs,	  chemical	  compounds	  and	  antistaphylococcal	  agents	  on	  
leukocyte	  function	  in	  response	  to	  S.	  aureus	  have	  also	  been	  elucidated.	  The	  studies	  on	  
antibiotics,	  however,	  may	  be	  outdated	  with	  the	  emergence	  of	  multi-­‐resistant	  
staphylococci.	  Although	  beyond	  the	  scope	  of	  this	  review,	  some	  immunomodulatory	  
approaches	  deserves	  mention.	  In	  brief,	  gamma	  interferon	  was	  shown	  to	  increase	  
neutrophil	  reaction	  and	  ROS	  production	  in	  response	  to	  staphylococcal	  formylated	  
peptides	  in	  vitro	  (181).	  In	  contrast	  to	  this,	  IL-­‐10	  decreased	  neutrophil	  phagocytosis	  of	  
serum-­‐opsonized	  S.	  aureus	  but	  left	  other	  effector	  functions	  unaltered	  (182).	  IL-­‐1β	  was	  
then	  identified	  as	  an	  important	  cytokine	  in	  the	  neutrophil	  recruitment	  to	  staphylococcal	  
infection	  (183).	  IL-­‐1β	  also	  gave	  abscess	  formation	  (184)	  -­‐	  a	  true	  hallmark	  of	  
staphylococcal	  infection.	  Both	  studies	  were	  conducted	  in	  mice.	  	  
Staphylococcal	  TLR	  interaction	  
Regarding	  specific	  staphylococcal-­‐TLR	  interaction,	  there	  is	  recent	  solid	  documentation	  
that	  diverse	  S.	  aureus	  components	  are	  recognized	  by	  TLR2	  (185,	  186).	  These	  include	  the	  
many	  lipoproteins	  in	  particular	  (187),	  but	  LTA	  (188,	  189),	  peptidoglycan	  (190)	  and	  PVL	  
(191)	  have	  also	  been	  suggested.	  However,	  both	  peptidoglycan	  and	  LTA	  have	  been	  
shown	  to	  stimulate	  TLR2	  in	  extremely	  high	  concentrations	  only,	  or	  not	  through	  TLR2	  at	  
all	  (192,	  193).	  Indeed,	  Hattar	  et	  al.	  suggested	  that	  LTA	  preparations	  were	  contaminated	  
with	  lipoprotein.	  Nevertheless,	  peptidoglycan	  was	  proposed	  to	  bind	  intracellular	  NOD-­‐
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receptors	  and	  potentiate	  the	  effects	  of	  other	  TLR2	  agonists	  such	  as	  LTA	  and	  LPS	  through	  
increased	  expression	  of	  CD14,	  TLR2	  and	  TLR4	  (194,	  195).	  Also,	  whole	  S.	  aureus	  has	  been	  
shown	  to	  stimulate	  dendritic	  cells	  via	  TLR9	  (196).	  
Importantly,	  much	  of	  the	  staphylococcal	  sensing	  through	  PRRs	  requires	  important	  co-­‐
receptors	  such	  as	  CD36	  and	  CD14	  (197).	  For	  instance,	  CD14	  is	  now	  shown	  to	  associate	  
with	  at	  least	  TLRs	  2,	  3,	  4,	  6,	  7	  and	  9	  (102).	  Yet	  many	  aspects	  of	  the	  staphylococcal	  
recognition	  by	  PRRs	  are	  still	  unknown.	  	  
What	  we	  do	  know	  is	  that	  several	  of	  the	  staphylococcal	  components	  activate	  PRRs	  to	  
initiate	  inflammation.	  This	  happens	  through	  complement	  activation,	  as	  discussed	  above,	  
and	  most	  probably	  through	  TLR	  activation	  as	  well.	  For	  one	  thing,	  TLR2	  deficient	  mice	  
are	  highly	  susceptible	  to	  staphylococcal	  infections	  (198).	  In	  this	  regard,	  it	  is	  interesting	  
that	  the	  staphylococcal	  exotoxin	  SSL3	  blocks	  TLR2	  activation	  on	  macrophages	  and	  thus	  
prevents	  downstream	  cytokine	  release	  (199).	  Peptidoglycan	  and	  LTA	  induce	  release	  of	  
TNF,	  IL-­‐6	  and	  IL-­‐10	  in	  human	  whole	  blood	  (200),	  IL-­‐1beta	  (201)	  and	  LTB4,	  IL-­‐8,	  MCP-­‐1	  
and	  G-­‐CSF	  (116).	  Furthermore,	  peptidoglycan	  and	  LTA	  are	  shown	  to	  synergistically	  
promote	  shock	  and	  multiple	  organ	  failure	  in	  several	  studies	  of	  sepsis,	  both	  in	  rats	  (202,	  
203)	  and	  pigs	  (204).	  Indeed,	  the	  involvement	  of	  peptidoglycan	  and	  LTA	  in	  sepsis	  was	  
recently	  summarized	  in	  an	  extensive	  review	  (205),	  but	  an	  adequate	  explanation	  of	  their	  
role	  in	  the	  septic	  pathogenesis	  was	  not	  offered.	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Figure	  5:	  PMNs,	  monocytes	  and	  macrophages	  versus	  S.	  aureus.	  Staphylococcal	  virulence	  factors	  are	  marked	  in	  
red.	  Sspb	  =	  Staphopain	  B,	  LukAB	  =	  Leukotoxin	  AB,	  CHIPS	  =	  Chemotaxis	  inhibitory	  protein	  of	  S.	  aureus,	  SSL-­‐5	  =	  
Superantigen-­‐like	  protein	  5,	  PVL	  =	  Panton-­‐Valentin	  Leukocidin,	  PSM	  =	  Phenol-­‐soluble	  modulin,	  Eap	  =	  
Extracellular	  adherence	  protein.	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The	  coagulation	  and	  fibrinolytic	  systems	  
Coagulation	  
The	  last	  passage	  of	  this	  review	  concerns	  the	  plasma	  cascade	  systems	  of	  coagulation	  and	  
fibrinolysis.	  Closely	  linked	  to	  the	  other	  plasma	  cascades	  throughout	  evolution,	  the	  
process	  of	  hemostasis	  is	  clearly	  involved	  in	  the	  resolution	  of	  danger,	  inflammation	  and	  
homeostasis.	  Indeed,	  as	  with	  complement	  activation,	  the	  coagulation	  system	  balances	  
between	  hypoactivation	  and	  hyperactivation	  thereby	  preventing	  hemorrhage	  or	  
thrombosis,	  respectively.	  However,	  thrombosis	  or	  intravascular	  clot	  formation	  has	  also	  
recently	  been	  proposed	  involved	  in	  physiological	  inflammation.	  
The	  process	  of	  coagulation	  or	  blood	  clotting	  is	  closely	  related	  to	  the	  formation	  of	  a	  
platelet	  plug	  in	  primary	  hemostasis.	  Coagulation	  may	  also	  occur	  regardless	  of	  platelet	  
plug	  formation	  (206).	  Briefly,	  the	  formation	  of	  a	  fibrinogen-­‐covered	  platelet	  plug	  is	  
considered	  the	  third	  step	  in	  hemostasis	  following	  initial	  vasoconstriction	  and	  increased	  
tissue	  pressure.	  Blood	  coagulation	  or	  clot	  formation	  through	  strictly	  controlled	  
proteolysis	  of	  plasma	  coagulation	  factors	  is	  the	  fourth	  step.	  
As	  with	  complement	  activation,	  blood	  clotting	  can	  be	  considered	  a	  "branching	  tree"	  
where	  different	  pathways	  of	  activation	  converge	  on	  a	  final	  common	  pathway.	  Although	  
this	  convention	  is	  highly	  simplified	  by	  omitting	  all	  the	  cross-­‐talk	  both	  between	  the	  
different	  pathways	  and	  back	  and	  forth	  between	  "upstream"	  and	  "downstream"	  events,	  it	  
does	  offer	  some	  perspective.	  
The	  so-­‐called	  intrinsic	  or	  contact-­‐dependent	  pathway	  is	  initiated	  by	  collagen,	  a	  
negatively	  charged	  surface	  (such	  as	  that	  of	  an	  activated	  platelet	  or	  circulating	  
microparticle)	  or	  platelet-­‐bound	  high-­‐molecular-­‐weight	  kinogen	  (HMWK)	  that	  mediates	  
the	  formation	  of	  activated	  factor	  XII	  (Hageman	  factor),	  i.e.	  XIIa	  for	  short.	  XIIa	  then	  
converts	  prekallikrein	  to	  kallikrein,	  which	  accelerates	  the	  conversion	  of	  XII	  to	  XIIa	  in	  a	  
positive	  feedback	  fashion,	  and	  also	  activates	  factor	  XI	  to	  XIa.	  Of	  note,	  kallikrein	  also	  
cleaves	  HMWK	  to	  release	  bradykinin,	  a	  potent	  vasodilator	  and	  pro-­‐inflammatory	  
mediator	  (18).	  XIa	  -­‐	  as	  Va	  and	  IIa	  -­‐	  cleaves	  VII	  to	  VIIa.	  VIIa	  forms	  a	  quaternary	  complex	  
with	  XIa,	  calcium	  and	  negatively	  charged	  phospholipids	  on	  the	  platelet	  surface	  known	  as	  
the	  (intrinsic)	  tenase.	  The	  tenase	  cleaves	  factor	  X	  to	  Xa.	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Similarly,	  the	  extrinsic	  pathway	  is	  initiated	  through	  tissue	  factor,	  TF	  (prothrombinase	  or	  
factor	  III)	  exposed	  to	  the	  circulation.	  TF	  is	  constitutively	  expressed	  in	  non-­‐vascular	  cells	  
and	  is	  inducible	  in	  especially	  circulating	  monocytes,	  neutrophils	  and	  microparticles	  
(207),	  thus	  exposed	  following	  endothelial	  damage	  and	  inflammation.	  TF	  mediates	  VIIa	  
generation	  and	  TF,	  VIIa	  and	  calcium	  form	  a	  tertiary	  (extrinsic)	  tenase	  also	  generating	  Xa.	  
The	  final	  common	  pathway	  is	  therefore	  initiated	  by	  Xa,	  which	  mediates	  Va	  formation.	  Xa,	  
Va	  and	  calcium	  form	  a	  prothrombinase	  complex.	  As	  the	  name	  implies,	  prothrombinase	  
generates	  thrombin	  from	  prothrombin.	  Thrombin,	  therefore,	  is	  at	  the	  heart	  of	  
coagulation.	  It	  has	  three	  main	  purposes.	  First,	  it	  converts	  fibrinogen	  to	  fibrin	  monomers,	  
which	  spontaneously	  and	  immediately	  polymerize,	  and	  then	  stabilize	  by	  XIIIa,	  also	  
generated	  by	  thrombin.	  Second,	  thrombin	  accelerates	  VIIa	  and	  Va	  generation	  through	  
positive	  feedback	  and	  third,	  activates	  endothelium	  and	  platelets	  (206).	  
Fibrinolysis	  and	  anticoagulation	  
Reversely,	  this	  system	  is	  counterbalanced	  by	  several	  paracrine	  and	  anticoagulant	  factors,	  
mainly	  originating	  from	  the	  endothelium.	  These	  include	  the	  tissue-­‐factor	  pathway	  
inhibitor	  (TFPI),	  targeting	  the	  prothrombinase,	  the	  antithrombin	  III	  (AT	  III),	  targeting	  
thrombin	  and	  Xa	  as	  well	  as	  thrombomodulin	  binding	  thrombin	  to	  the	  endothelial	  
surface	  and	  subsequently	  activating	  protein	  C,	  which,	  by	  the	  aid	  of	  co-­‐factor	  protein	  S,	  
inactivates	  factors	  VIIa	  and	  Va.	  Furthermore,	  in	  the	  event	  of	  clot	  formation,	  it	  can	  be	  
degraded	  through	  fibrinolysis	  by	  plasmin	  formed	  from	  plasminogen	  by	  either	  the	  
endothelial	  tissue	  plasminogen	  activator	  (t-­‐PA)	  or	  urokinase-­‐type	  plasminogen	  activator	  
(u-­‐PA).	  Naturally,	  these	  can	  also	  be	  counter-­‐balanced	  by	  two	  other	  serine	  protease	  
inhibitors	  (serpins),	  namely	  the	  plasminogen	  activator	  inhibitors	  1	  and	  2	  (PAI-­‐I,	  -­‐II).	  Of	  
these	  PAI-­‐I	  is	  clearly	  the	  most	  relevant.	  Figure	  6	  provides	  a	  schematic	  overview.	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Figure	  6:	  The	  coagulation	  system	  generating	  fibrin	  and	  the	  fibrinolytic	  system	  degrading	  it	  to	  fibrin-­‐
degradation	  products	  (FDPs).	  HMWK	  =	  High	  molecular	  weight-­‐kinogen,	  APC	  =	  Activated	  protein	  C,	  PL-­‐	  =	  
negatively	  charged	  phospholipids,	  TFPI	  =	  Tissue	  factor	  pathway	  inhibitor,	  ATIII	  =	  Antithrombin	  III,	  t-­‐PA	  =	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Evidently,	  the	  clotting	  cascade	  and	  consequent	  fibrinolysis	  is	  potent	  and	  must	  be	  strictly	  
controlled.	  However,	  during	  inflammation	  and	  sepsis	  this	  control	  is	  lost	  leading	  to	  
simultaneous	  thrombosis	  and	  hemorrhage.	  In	  severe	  sepsis,	  disseminated	  intravascular	  
coagulation	  (DIC)	  is	  characterized	  my	  microthrombi	  and	  diffuse	  fibrin	  deposition	  that	  
occlude	  capillaries	  and	  cause	  multiple-­‐organ	  failure,	  but	  also	  profuse	  bleeding	  in	  other	  
areas	  such	  as	  the	  skin.	  Thus,	  DIC	  is	  strongly	  associated	  with	  higher	  mortality	  in	  sepsis,	  
and	  its	  interrelation	  with	  inflammation	  is	  complex	  and	  potentially	  devastating	  as	  the	  
two	  processes	  activate	  and	  perpetuate	  each	  other	  (208).	  However,	  as	  mentioned,	  the	  
two	  may	  not	  be	  different	  entities.	  A	  recent	  review	  identifies	  the	  intriguing	  process	  of	  
immunothrombosis	  as	  a	  novel	  component	  of	  the	  innate	  immune	  system	  (209).	  Here,	  the	  
authors	  propose	  that	  immunothrombosis	  has	  several	  different	  physiological	  functions:	  
Pathogens	  are	  trapped	  and	  unable	  to	  disseminate	  as	  microvessels	  are	  sealed	  with	  
microthrombi.	  In	  doing	  so,	  immunothrombosis	  generates	  a	  closed	  compartment	  ideal	  
for	  pathogen	  recognition	  and	  killing.	  Furthermore,	  fibrinogen	  and/or	  fibrin	  enhance	  the	  
immune	  response	  through	  immune	  cell	  recruitment	  whilst	  NETosis	  is	  highly	  dependent	  
on	  its	  procoagulant	  properties	  for	  optimal	  effect.	  However,	  the	  authors	  identify	  DIC	  as	  a	  
form	  of	  aberrant	  immunothrombosis.	  Whereas	  microthrombi	  and	  fibrin	  deposition	  
allow	  sufficient	  organ	  perfusion	  and	  tissue	  oxygenation	  under	  physiological	  conditions,	  
they	  may	  strangulate	  these	  same	  organs	  in	  sepsis	  and	  DIC,	  causing	  multiple	  organ	  
failure.	  What	  favors	  immunothrombosis	  to	  DIC	  is	  still	  unknown,	  but	  some	  clues	  might	  be	  
found	  in	  the	  multiple	  interactions	  between	  host	  coagulation	  and	  pathogen	  -­‐	  the	  next	  
topic	  of	  this	  review.	  
Coagulation,	  fibrinolysis	  and	  Staphylococcus	  aureus	  
Staphylococcal	  coagulases	  
Staphylococci	  activate	  the	  coagulation	  system	  through	  several	  MSCRAMMs.	  Notably,	  the	  
ability	  of	  surface-­‐bound	  staphylocoagulase	  (Coa)	  to	  bind	  and	  activate	  prothrombin,	  
yielding	  staphylothrombin	  is	  widely	  used	  to	  diagnose	  S.	  aureus	  infections	  (210).	  To	  date,	  
ten	  different	  serotypes	  of	  Coa	  have	  been	  described	  (211).	  Likewise,	  the	  von	  Willebrand	  
factor-­‐binding	  protein	  (vWbp)	  is	  identified	  as	  a	  coagulase	  (212),	  and	  both	  coagulases	  
have	  to	  function	  to	  resist	  neutrophils	  and	  to	  form	  abscesses	  (213).	  Indeed,	  it	  is	  proposed	  
that	  staphylococci	  secrete	  Coa	  and	  vWbp	  to	  generate	  provisional	  pseudocapsules	  on	  the	  
bacterial	  surface	  and	  avoid	  recognition	  by	  the	  immune	  system	  during	  their	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dissemination	  (214).	  It	  is	  now	  shown	  that	  the	  coagulases	  associate	  with	  factor	  XIII	  in	  
addition	  to	  fibrinogen,	  von	  Willebrand	  factor	  and	  prothrombin	  to	  enhance	  fibrin	  
generation	  (215).	  Interestingly,	  most	  S.	  aureus	  strains	  also	  secrete	  staphylokinase,	  a	  
potent	  activator	  of	  the	  fibrinolytic	  system	  (216,	  217)	  and	  inactivator	  of	  neutrophil-­‐
derived	  antimicrobial	  peptides	  (218).	  Equally,	  secreted	  staphylococcal	  aureolysin	  is	  
proposed	  to	  activate	  the	  fibrinolytic	  system	  at	  several	  levels,	  converting	  plasminogen	  to	  
angiostatin	  and	  mini-­‐plasminogen,	  degrading	  PAI-­‐1	  and	  neutralizing	  the	  otherwise	  
inhibitory	  effects	  of	  alpha(2)-­‐antiplasmin	  (219).	  It	  is	  therefore	  tempting	  to	  speculate	  
that	  staphylococci	  first	  cover	  themselves	  in	  fibrin	  by	  way	  of	  the	  coagulases	  and	  then	  
undress	  at	  suitable	  locations	  by	  way	  of	  the	  staphylokinase,	  but	  this	  is	  still	  unclear.	  
Staphylococci	  and	  infective	  endocarditis	  
A	  particular	  presentation	  of	  invasive	  S.	  aureus	  infection	  is	  the	  ability	  to	  damage	  and	  
adhere	  to	  previously	  undamaged	  heart	  valves	  causing	  infective	  endocarditis.	  Although	  
the	  precise	  mechanisms	  behind	  this	  remains	  unknown,	  endothelial	  cell	  and	  platelet	  
activation	  are	  key	  events.	  Platelet	  activation	  and	  aggregation	  is	  promoted	  by	  
staphylococcal	  surface	  components	  such	  as	  the	  clumping	  factors	  A	  and	  B	  (Clf	  A	  and	  B)	  
(220),	  which	  bind	  fibrinogen,	  and	  protein	  A	  (221),	  but	  also	  through	  increased	  monocyte	  
TF	  expression	  (222)	  as	  well	  as	  in	  a	  fibrinogen-­‐independent,	  complement	  dependent	  
fashion	  (223).	  Equally,	  endothelial	  cells	  treated	  with	  fibronectin-­‐binding	  protein	  A,	  but	  
not	  B	  and	  not	  clumping	  factor	  A	  caused	  a	  markedly	  procoagulant	  response	  in	  the	  
vasculature.	  Later,	  soluble	  fibrin	  was	  identified	  as	  a	  main	  bridge	  between	  staphylococci	  
and	  platelets	  (224).	  Thus,	  coagulation	  activation	  is	  an	  important	  virulence	  factor	  in	  
infective	  endocarditis.	  
S.	  aureus,	  coagulation	  and	  sepsis	  
Not	  surprisingly,	  therefore,	  coagulation	  is	  also	  activated	  in	  staphylococcal	  sepsis.	  In	  
experimental	  whole-­‐blood	  models,	  staphylococcal	  α-­‐toxin	  is	  shown	  to	  not	  only	  lyse	  
platelets	  but	  also	  and	  more	  importantly,	  to	  promote	  assembly	  of	  the	  prothrombinase	  
through	  platelet	  activation	  (225).	  Equally,	  the	  staphylococcal	  superantigens	  
enterotoxins	  A	  and	  B,	  as	  well	  as	  the	  toxic	  shock	  syndrome	  toxin	  1	  (TSST-­‐1)	  induced	  an	  
IL-­‐1β-­‐dependent,	  TF-­‐mediated	  procoagulant	  response	  in	  whole	  blood	  (226).	  
Furthermore,	  a	  subsequent	  study	  identified	  peptidoglycan	  but	  not	  LTA	  as	  an	  important	  
procoagulant	  in	  human	  whole	  blood	  (227).	  This	  was	  later	  also	  shown	  in	  human	  
	   34	  
umbilical	  vein	  endothelial	  cells	  (HUVECs).	  Peptidoglycan,	  LTA	  and	  TSST-­‐1	  all	  induced	  
increased	  TF	  mRNA	  transcription	  and	  TF	  expression,	  but	  only	  peptidoglycan	  increased	  
ICAM	  and	  VCAM	  on	  the	  HUVECs	  as	  well	  (228).	  Furthermore,	  heat-­‐inactivated	  S.	  aureus	  
induced	  an	  imbalanced	  increase	  in	  PAI-­‐1	  expression	  in	  peritoneal	  mesothelial	  cells	  in	  
one	  study	  (229),	  whereas	  decreased	  fibrinolytic	  activity	  in	  peritonitis	  was	  attributed	  to	  
S.	  aureus-­‐induced	  mestothelial	  cell	  death	  in	  another	  (230).	  In	  contrast,	  the	  staphopains	  
are	  shown	  to	  increase	  clotting	  time	  through	  fibrinogen	  degradation	  (231).	  Also,	  MBL	  
deficiency	  has	  been	  shown	  to	  promote	  DIC	  in	  mice	  (232).	  Even	  though	  MBL	  and	  its	  
MASPs	  are	  identified	  as	  activators	  of	  coagulation	  in	  the	  same	  study,	  the	  literature	  
presented	  in	  this	  review	  suggests	  that	  S.	  aureus	  generally	  activates	  coagulation	  rather	  
than	  prevents	  it.	  Indeed,	  murine	  S.	  aureus	  sepsis	  induced	  a	  hypercoaguable	  state	  with	  
increased	  TF	  activity	  (233),	  whereas	  in	  a	  porcine	  model	  of	  intravenous	  S.	  aureus	  sepsis	  
the	  researchers	  found	  pulmonary	  petecchiae	  and	  several	  thrombotic	  lesions	  in	  
association	  with	  staphylococcal	  abscesses	  as	  well	  as	  increased	  coagulability	  over	  time,	  
measured	  by	  thromboelastography	  (234).	  The	  same	  group	  later	  found	  that	  the	  septic	  
pigs	  in	  the	  model	  developed	  DIC	  in	  accordance	  with	  human	  criteria	  (235).	  	  
In	  line	  with	  these	  findings,	  measures	  have	  been	  taken	  to	  reduce	  the	  hypercoagulability	  
in	  sepsis.	  Although	  recombinant	  human	  activated	  protein	  C	  was	  withdrawn	  as	  a	  licensed	  
drug	  in	  non-­‐specific	  sepsis,	  a	  novel	  study	  of	  murine	  staphylococcal	  sepsis	  gave	  
promising	  results	  when	  blocking	  Coa,	  vWBp	  and	  ClfA	  (236)	  -­‐	  All	  20	  mice	  receiving	  the	  
treatment	  survived,	  none	  in	  the	  untreated	  group.	  Interestingly,	  the	  procoagulant	  effects	  
of	  staphylococci	  may	  even	  prevail	  for	  a	  long	  time	  following	  resolution	  of	  the	  infection.	  A	  
recent	  large	  study	  revealed	  increased	  patient	  risk	  of	  a	  venous	  thromboembolic	  episode	  
(VTE)	  within	  the	  first	  year	  following	  S.	  aureus	  bacteremia	  (237).	  Although	  the	  exact	  
pathogenesis	  of	  VTEs	  is	  currently	  unclear,	  the	  many	  interactions	  between	  S.	  aureus	  and	  
the	  coagulation	  system	  quite	  probably	  contribute	  to	  the	  hemostatic	  dysfunction.	  
	   35	  
	  
Figure	  7:	  S.	  aureus,	  coagulation	  and	  fibrinolysis.	  Different	  points	  of	  staphylococcal	  interaction	  are	  marked	  in	  
red	  whereas	  the	  physiological	  inhibitors	  are	  left	  out	  of	  this	  figure.	  TSST-­‐1	  =	  Toxic	  shock	  syndrome	  toxin	  1,	  
LTA	  =	  Lipoteichoic	  acid,	  TF	  =	  Tissue	  factor.	  vWbp	  =	  von	  Willebrand	  binding	  protein,	  Coa	  =	  Coagulase,	  Ssps	  =	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Discussion	  and	  concluding	  remarks	  
Evidently,	  S.	  aureus	  infection	  strongly	  intertwines	  with	  the	  innate	  immune	  system,	  
illustrated	  by	  the	  numerous	  interactions	  with	  the	  complement	  system,	  the	  coagulation	  
system	  and	  the	  leukocytes	  documented	  in	  this	  review.	  The	  question	  remains,	  however,	  if	  
the	  many	  immune	  evasive	  strategies	  -­‐	  inactivating	  complement,	  killing	  neutrophils	  and	  
activating	  coagulation	  is	  really	  what	  makes	  the	  staphylococcal	  infections	  threatening	  to	  
the	  host?	  Or	  rather,	  if	  the	  bacteria	  simply	  activate	  these	  systems	  and	  the	  true	  damage	  
actually	  is	  caused	  by	  the	  body	  itself?	  Indeed,	  the	  many	  sophisticated	  virulence	  factors	  of	  
S.	  aureus	  promote	  its	  infection,	  dissemination	  and	  survival	  during	  orderly,	  localized	  
infection.	  For	  instance,	  a	  recent	  study	  demonstrated	  significant	  association	  between	  
increased	  activity	  in	  genes	  coding	  for	  capsular	  polysaccharides	  5	  and	  8,	  adhesins,	  PVL,	  
serine	  proteases	  (V8)	  and	  SCIN	  and	  invasive	  disease	  (238).	  However,	  this	  may	  not	  be	  the	  
case	  in	  sepsis.	  	  
Nonetheless,	  infection	  and	  immune	  response	  act	  in	  synergy.	  In	  line	  with	  findings	  for	  
non-­‐specific	  sepsis,	  both	  delayed	  antibiotic	  treatment	  and	  septic	  shock	  are	  clearly	  
negative	  predictive	  factors	  in	  staphylococcal	  sepsis	  (239).	  Equally,	  in-­‐hospital	  patients	  
suffering	  from	  S.	  aureus	  sepsis	  have	  an	  excess	  one-­‐year	  mortality	  of	  20	  per	  cent	  
compared	  to	  non-­‐septic	  patients,	  as	  well	  as	  increased	  morbidity	  and	  cost	  of	  stays,	  
underlining	  the	  difficulties	  of	  this	  particular	  pathogen	  (240).	  However,	  few	  studies	  
document	  the	  patterns	  of	  sepsis	  caused	  by	  different	  microbes.	  In	  general,	  Gram-­‐positive	  
strains	  are	  shown	  to	  induce	  a	  more	  delayed	  release	  of	  cytokines	  compared	  to	  Gram-­‐
negative	  strains,	  as	  Gram-­‐positive	  bacteria	  often	  demand	  a	  more	  complex	  immune	  
response,	  and	  Gram-­‐negative	  strains	  cause	  a	  more	  profound	  and	  immediate	  
hemodynamic	  dysfunction,	  at	  least	  in	  animal	  models	  (241).	  Furthermore,	  therapies	  
targeting	  individual	  cytokines	  such	  as	  TNF	  have	  been	  more	  promising	  in	  Gram-­‐negative	  
animal	  models	  of	  sepsis	  compared	  to	  Gram-­‐positive	  models.	  Yet	  the	  hope	  of	  finding	  the	  
"magic	  bullet"	  or	  "one	  size	  fits	  all"-­‐therapy	  in	  sepsis	  is	  now	  small.	  For	  instance,	  multiplex	  
analysis	  of	  17	  different	  cytokines	  over	  seven	  days	  in	  30	  septic	  patients	  did	  not	  find	  a	  
unique	  mediator	  related	  to	  patient	  outcome.	  Although	  high	  levels	  of	  monocyte	  
chemotactic	  protein	  (MCP)-­‐1,	  macrophage	  inflammatory	  protein	  (MIP)-­‐1beta	  and	  IL-­‐8	  
were	  associated	  with	  higher	  mortality	  the	  first	  three	  days,	  all	  cytokines	  were	  generally	  
elevated	  among	  non-­‐survivors	  (242).	  Therefore,	  interesting	  concepts	  have	  emerged,	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such	  as	  the	  idea	  of	  an	  early	  and	  broad	  attenuation	  of	  the	  immune	  response	  through	  
blocking	  early	  sensing	  of	  pathogen	  by	  complement	  and	  leukocytes	  rather	  than	  trying	  to	  
take	  out	  single	  mediators	  further	  down	  the	  line	  (243).	  This	  concept	  can	  be	  seen	  as	  
preventing	  a	  flood	  downstream	  by	  building	  a	  dam	  upstream	  or	  disarming	  a	  bomb	  before	  
it	  blows.	  The	  only	  trouble	  is	  getting	  to	  the	  bomb	  soon	  enough	  -­‐	  most	  patients	  probably	  
enter	  the	  clinic	  long	  after	  detonation,	  at	  a	  point	  where	  "downstream"	  intervention	  is	  the	  
only	  possibility.	  Even	  so,	  it	  is	  important	  to	  identify	  high-­‐risk	  patients	  before	  they	  
develop	  sepsis	  and	  preventive	  strategies	  are	  currently	  the	  best	  solution	  to	  sepsis.	  
Similar	  strategies	  are	  under	  investigation	  such	  as	  preventing	  staphylococcal	  nasal	  
colonization.	  Equally,	  sepsis	  is	  a	  very	  comprehensive	  disease	  entity	  where	  patients	  
present	  very	  differently.	  It	  also	  strikes	  at	  the	  very	  extremes	  of	  age	  and	  it	  is	  worth	  
considering	  whether	  old	  patients,	  in	  particular,	  are	  over-­‐exposed	  to	  infection	  and	  sepsis	  
because	  of	  too	  much	  invasive	  intervention.	  Nonetheless,	  sepsis	  causes	  a	  huge	  disease	  
burden	  through	  its	  morbidity,	  costs	  and	  difficulty	  to	  manage.	  More	  knowledge	  on	  the	  
complex	  interactions	  between	  the	  different	  pathogens	  and	  the	  immune	  system	  in	  both	  
health	  and	  disease	  is	  needed.	  We	  could	  then	  unveil	  and	  test	  suitable	  targets	  of	  
intervention	  to	  ultimately	  improve	  the	  outcome	  in	  sepsis.	  For	  the	  case	  of	  Staphylococcus	  
aureus	  we	  now	  know	  a	  lot	  about	  virulence	  factors	  but	  less	  about	  how	  to	  combat	  them.	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